UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________________________________

FORM 10-K

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, ~~2024~~2025

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission ~~file~~File ~~number~~Number: 333-~~267039~~146758

_____________________________________

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Colorado	84-4901299
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

6201 Bonhomme Road, Suite 435N, Houston, TX	77036
(Address of Principal Executive Office)	(ZIP Code)

Registrant’s telephone number, including area code: (214) 733-0868

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act: None

_____________________________________

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒ No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ☐ Yes ☒ No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

	Large accelerated filer ☐	Accelerated filer ☐
	Non-accelerated filer ☒	Smaller reporting company ☒
		Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No

Aggregate market value of registrant’s ~~common~~ common stock held by non-affiliates of the registrant, based upon the closing price of a share of the registrant’s common stock on November 29, 2024 (the last trading day before November 30, ~~2023~~2024, as reported by on Nasdaq.com: approximately $32.7 9 million.

Number of shares of the registrant’s common stock outstanding as of September 1022, ~~2024~~2025: 1011,~~431~~626,749,347.

DOCUMENTS INCORPORATED BY REFERENCE

None.

Table of Contents

PART I

Item 1.	Business	1
Item 1A.	Risk Factors	1214
Item 1B.	Unresolved Staff Comments	1214
Item 1C.	Cybersecurity	1214
Item 2.	Properties	1215
Item 3.	Legal Proceedings	1215
Item 4.	Mine Safety Disclosures	1215

PART II

Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities	1316
Item 6.	[Reserved]	1316
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1316
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	1720
Item 8.	Financial Statements and Supplementary Data	1821
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	1922
Item 9A.	Controls and Procedures	1922
Item 9B.	Other Information	2023
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	2023

PART III

Item 10.	Directors, Executive Officers and Corporate Governance	2124
Item 11.	Executive Compensation	2326
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	2629
Item 13.	Certain Relationships and Related Transactions, and Director Independence	2729
Item 14.	Principal Accountant Fees and Services	2932

PART IV

Item 15.	Exhibits and Financial Statement Schedules	3033
Item 16.	Form 10-K Summary	3134
Signatures		3235

CAUTIONARY NOTES

Forward-Looking Statements

This Annual Report on Form 10-K, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Report, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management, and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “goal,” “objective,” “seeks,” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions. Forward-looking statements contained in this Report include, but are not limited to, our expectations regarding our financial performance; our expectations regarding future operating performance; our ability to attract and retain customers; our ability to compete in our industries; our ability to meet our liquidity needs; our ability to effectively manage our exposure to fluctuations in foreign currency exchange rates; the increased expenses associated with being a public company; the size of our addressable markets, market share, and market trends, including our ability to grow our business in the countries we have identified as near- term priorities; anticipated trends, developments, and challenges in our industry, business, and the highly competitive markets in which we operate; our ability to anticipate market needs or develop new or enhanced offerings and services to meet those needs; our ability to manage expansion into international markets and new industries; our ability to comply with laws and regulations, including laws affecting the cannabis and pharmaceutical industries, that currently apply or may become applicable to our business both in the United States and internationally; our ability to effectively manage our growth and expand our infrastructure and maintain our corporate culture; our ability to identify, recruit, and retain skilled personnel, including key members of senior management; our ability to successfully defend litigation brought against us; our ability to successfully identify, manage, and integrate any existing and potential acquisitions; our ability to maintain, protect, and enhance our intellectual property.

You should not rely upon forward-looking statements as predictions of future events. We have based the forward-looking statements in this Report primarily on our current expectations, estimates, forecasts, and projections about future events and trends that we believe may affect our business, results of operations, financial condition, and prospects. Although we believe that we have a reasonable basis for each such forward-looking statement, we cannot guarantee that the future results, activity levels, performance, or events and circumstances reflected in the forward-looking statements will be achieved. The outcome of the events described or discussed in these forward-looking statements is subject to risks, uncertainties, and other factors described in this Report. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and we cannot predict all of them that could have an impact on these forward-looking statements. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.

The forward-looking statements in this Report relate only to events or circumstances as of the date on which they are made. We undertake no obligation to update any forward-looking statement in this Report to reflect events or circumstances after the date of this Report or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may make.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Such statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you should not unduly rely upon them.

You should read this Report and the documents referred to in it completely and with the understanding that our actual future results may be materially different from what we expect. All forward-looking statements in this Report are qualified by these cautionary statements.

Third-Party Information

This Report includes information and estimates based on reports and other publications, sources from industry analysts, market research firms and other independent sources that were generally available to the public and not commissioned by us, in addition to management’s good-faith estimates and analyses. We believe that such reports and publications are reliable, but have not independently verified them or their underlying data sources, methodologies or assumptions. They contain information and estimates that are based on estimates, forecasts, projections, market research, or similar methodologies and are inherently subject to uncertainties. Actual events or circumstances may differ materially from events and circumstances reflected in these reports.

Descriptions of Contracts

This Report may contain descriptions of contracts and instruments to which the Company or its officers and directors are parties or by which it is affected. These contracts and instruments are exhibits to this Report and are identified in Item 16, Exhibits, Financial Statement Schedules. Where any such contract or instrument is described in this Report, you are referred to the related exhibit, which may be found on the SEC’s website, and the description thereof is qualified by such reference.

iii

PART I

Item 1.

Business.

History

Overview

The Company was formed in Colorado on February 28, 2003, as a limited liability company under the name Fidelity Aircraft Partners LLC. On December 16, 2009, it converted to a corporation under the name Fidelity Aviation Corporation, and on August 24, 2004, it changed its name to China Infrastructure Construction Corp. On February 28, 2018, the Company changed its name to Hippocrates Direct Healthcare, Inc., and on December 6, 2022, it changed its corporate name to Cannabis Bioscience International Holdings, Inc.

On December 20, 2019, the present management acquired control of the Company as a result of the acquisition of Pharmacology University, Inc. (see below). The Company began to file reports with OTC in 2018 under its Alternate Reporting Standard and has been a “Pink Sheet” company since then.

The Company’s vision is to provide superior services while adhering to its core values of integrity, respect, compassion, inclusiveness, social responsibility, excellence and innovation.

~~Acquisition~~The ofCompany ~~Pharmacology~~has ~~University~~three ~~Inc.~~businesses:

~~Pharmaceutical~~· ~~University Inc.(“PUI”) was incorporated in the State of Delaware on January 5, 2017. On December 20, 2019, PUI was merged with and into the Company.~~ The Company conducts ~~the~~a business ~~acquired~~generally byrelated ~~this~~to ~~merger~~cannabis-related ~~(the~~research ~~“Pharmacology~~and ~~University~~education ~~Business”)~~ under the trade name Pharmacology University~~. The~~ (the “Pharmacology University Business ~~is generally cannabis-related research and education~~”). For a more ~~detailed~~ description of the Pharmacology University Business, see “Business – Pharmacology University Business.”

~~Acquisition~~· The Company conducts clinical trials, some of ~~Precision~~which may involve cannabis and CBD products as a Sponsor and a CRO under the trade name Alpha Research Institute (the “Alpha Research Business’). For a description of the Alpha Research Business, see “Business – Alpha Research Business.”

On· ~~March~~The ~~31, 2019, the~~ Company ~~entered~~plans ~~into~~to ~~the Alpha Research Business by acquiring all of the outstanding units in Precision Research Institute~~manufacture, ~~LLC,~~market ~~a Texas limited liability company (“PRI”), which was formed on May 18, 2016, from the Company’s then president. On August 20, 2020, PRI was merged with~~ and ~~into~~sell ~~the~~CBD ~~Company.~~products ~~The Company conducts the Alpha Research Business~~ under the ~~trade~~ name ~~Alpha~~“VitaCookies” ~~Research Institute. As indicated under that caption,~~ (the ~~Company~~“CBD ~~intends to conduct clinical trials of cannabinoids as a Sponsor~~Business”). For a ~~detailed~~ description of the ~~Alpha~~CBD ~~Research~~ Business, see “Business – ~~Alpha~~CBD ~~Research~~ Business.”

~~Pharmacology~~The ~~University~~Company ~~Business~~is seeking to establish a prominent position in the field of scientific research and biotechnology applied to medicinal cannabis and to compete successfully with companies that have significantly larger financial resources. Despite operating with substantially lower capital, facilities and manpower, the Company is attempting to establish a strong foundation in scientific research and biotechnology and to attain scientific and clinical achievements that rival those of larger industry players. The Company has filed 10 applications for utility patents with the U.S. Patent and Trademark Office (USPTO) and plans to file 10 more. The company also holds 12 U.S. trademarks. The Company also has an intellectual property portfolio of more than 100 medical formulations for treating conditions including menopause, PTSD, dysbiosis, depression, and Alzheimer’s disease, along with scientific literature and educational audiovisual materials.

The Company has actively engaged in public policy and regulatory discourse. Along with firms that have invested substantial amounts in the cannabis industry, the Company was selected to participate in the Drug Enforcement Administration’s 2024 hearing on the rescheduling of marijuana from Schedule 1, where the Company’s representative gave testimony emphasizing the importance of scientific research, biotechnological development and regulated access to cannabis for medical purposes. These hearings have been paused, but the Company intends to participate in them when they resume to maintain its position in support of medical cannabis based on a strong bioscientific foundation.

The Cannabis Industry

The cannabis industry is fast-growing, increasingly complex, and rapidly changing. The Company believes that the growing cannabis industry in ~~numerous~~the ~~U.S.~~United ~~states~~ States and ~~other~~abroad ~~countries~~offers ~~represents~~ a significant market opportunity for ~~the~~its Pharmacology University Business, as persons involved in the industry need the educational and other services that it furnishes, as more fully described below.

The U.S. cannabis industry is undergoing rapid growth and change, particularly with the recent opening of opportunities for federally sanctioned research on cannabis in partnership with the Drug Enforcement Administration (the “DEA”), as well as the federal legalization of hemp and corresponding state and federal hemp research programs.

The legal cannabis market in the United States has shown sustained growth since reaching approximately $27 billion in sales in 2022 (Brightfield Group), with estimates placing the market value between $44 and $45 billion in 2025 (Grand View Research, Statista), around $50 billion by 2028 (Brightfield and Statista), and within a range of $67 to $76 billion by 2030 (Whitney Economics and Grand View Research), reaching as high as $87 billion by 2035 (Whitney Economics), which confirms its continuous expansion in both recreational and medical segments.

~~The~~In ~~cannabis~~ the medical market, ~~generally~~demand for iscannabis ~~large~~for research continues to accelerate, driven by ongoing legalization efforts and ~~growing~~strong public support. InAs ~~2023~~of early 2025, medical ~~according~~cannabis toremains ~~Brightfield’s~~legal ~~2023~~in 40 U.S. ~~Cannabis~~states, ~~Market~~four ~~Forecast~~of its five inhabited territories, and the ~~USA~~District of Columbia. While precise national estimates of registered medical cannabis patients are not uniformly reported, enrollment data from states with mandatory registries ~~market~~indicate ~~had~~that ~~approximately~~at ~~$27~~least 3.6 million inpatients ~~sales~~are incurrently ~~2022~~registered ~~and~~— isa ~~forecast~~notable toincrease from prior figures. Furthermore, projections suggest that the number of registered patients could reach ~~$50~~5.7 million by ~~2028~~2030, highlighting sustained growth trends in medical participation. The ~~According~~global tomedical cannabis market is also on a ~~report~~strong byupward ~~New~~trajectory. ~~Frontier~~In ~~Data~~2024, the Umarket was valued at approximately $12.S65 billion, and forecasts anticipate that it will expand at a compound annual growth rate (CAGR) of 24% through 2034, potentially reaching $108.7 billion ~~legal~~by ~~cannabis~~that ~~market~~year. isAnother ~~predicted~~projection toestimates ~~reach~~growth from $4114.534 billion in ~~sales~~2024 to $52.23 billion by 2034, at a CAGR of 13.8%. These trends reflect the widening scope of research interest: not only in states where medical cannabis is already legal, but in anticipation of broader state and potential federal legalization. Authorities like the DEA continue to respond by expanding aggregate production quotas for cannabis, aiming to meet increasing research demand — though specific quota figures for 2025 were not yet available at the time of reporting.

In ~~the~~ ~~medical market~~2024, the ~~demand~~leading ~~for cannabis for research is likely to increase significantly over the next few years and decades,~~pharmaceutical ~~due~~companies toworldwide ~~the~~invested ~~increasing~~approximately ~~number~~$288 ofbillion ~~states~~in ~~legalizing~~research ~~cannabis~~ and ~~the~~development ~~strong public support for cannabis legalization. By 2025~~(R&D), ~~5.4 million Americans, or 2.4% of U.S. adults, are predicted to be registered patients in medical cannabis states,~~ according to adata ~~report by~~from ~~New~~Evaluate ~~Frontier Data (“New Frontier”)~~Pharma BioSpace. ~~New~~In ~~Frontier also projects that~~ the ~~medical~~United ~~cannabis market will nearly double to over $16 billion in that time~~States, ~~taking~~this ~~into~~amount ~~account~~represents ~~more~~a ~~geographies~~significant ~~within~~portion ~~the U.S. legalizing cannabis, which will lead to market expansion, the normalization~~ of ~~cannabis, which will increase~~ the ~~number of consumers, and medical cannabis patients turning to cannabis as an alternative to prescription drugs. The~~ global ~~medical cannabis market is projected to reach $87~~total.4 ~~billion by 2027, according to Global Market Insights (“GMI”).~~ The ~~DEA’s~~private ~~aggregate~~R&D ~~production quotas for cannabis were 3,200 kg in 2022 for dried flower (an estimated $35 million~~ market~~) and 1~~,~~000~~ ~~kg for cannabis extract (an estimated $100 million market). These~~including ~~aggregate~~federal ~~production~~programs ~~quotas~~such ~~are~~as ~~expected~~those toof ~~continue increasing to meet~~ the ~~increasing~~DEA, ~~demand~~continues ~~for cannabis research in the U.S. In addition~~ to ~~government~~show ~~funding,~~interest ~~some institutions are already receiving private investment~~ in ~~cannabis~~investigating ~~research.~~the ~~For~~uses ~~example, Harvard~~ and ~~MIT~~risks ~~recently~~of ~~received a $9 million donation to fund research into~~ cannabis’ ~~influence on brain health~~ and ~~behavior.~~ ~~Additionally,~~hemp ~~Skylight Health Group (formerly named “CB2 Insights”) has noted that average prescriptions for qualifying conditions such as chronic pain~~derivatives, ~~PTSD, sleep disorders, epilepsy and anxiety saw a decline of 11% in favor of medical~~ ~~cannabis~~extending ~~replacement,~~beyond ~~leading~~ the ~~Company~~states ~~to estimate~~ that ~~more~~have ~~than~~legalized $4their ~~billion in sales that currently go to pharmaceutical products could be redirected towards~~ medical ~~cannabis~~use. Further research on cannabis legalization and its impact on public health is needed and is likely to take place over the coming years, as the DEA has recognized the increased need for cannabis-related research.

InCancer remains one of the ~~2019,~~primary ~~large~~drivers ~~pharmaceutical~~of ~~companies~~demand infor ~~the~~medical Ucannabis.S. ~~spent~~According ~~$83~~to ~~billion~~the onWorld ~~drug~~Health ~~research~~Organization (WHO), in 2022, there were nearly 20 million new cancer cases and ~~development~~9.7 ~~The~~million ~~private~~deaths, ~~research~~and ~~market~~projections indicate that by 2050, ~~like~~new cases will exceed 35 million, with mortality almost ~~the~~doubling. ~~federal~~In ~~DEA~~the ~~research~~United ~~program~~States, ~~has~~it anis ~~interest~~estimated that in ~~investigating~~2025, ~~the~~there ~~uses~~will be approximately 2,000,000 new cancer diagnoses and ~~risks~~600,000 ofdeaths from this disease. At the same time, medical cannabis is increasingly recognized as an alternative for chronic pain management: in Michigan, one study found its use was associated with a 64% reduction in opioid consumption, decreased medication use and ~~hemp~~side ~~derivatives~~effects, ~~not~~and ~~only~~improved quality of life. Likewise, patients with neuropathic pain reported a 73.5% decrease in ~~states~~monthly opioid dosages (MME), while those with ~~that~~primary ~~have~~chronic ~~legalized~~pain ~~medical~~achieved a 68% reduction. These findings underscore cannabis,’s ~~but~~potential ~~also~~as a therapeutic tool in ~~anticipation~~addressing both ofthe ~~potential~~rising ~~full~~global ~~legalization~~disease burden and the significant challenges posed by long-term opioid use.

The high prevalence of cancer is expected to be one of the factors driving the demand for legal cannabis. For instance, according to the World Health Organization (WHO), cancer is the second leading cause of death worldwide and was responsible for about 8.8 million deaths in 2015. In addition, the growing disease burden of chronic pain and significant side effects associated with opioid usage is expected to drive the demand for medical cannabis, which has proved to be a potent product for chronic pain management. The Company believes that these and other applications will lead to increased demand.

Expanding Legalization of Cannabis

~~The~~Cannabis 2018 Farm Bill in the U.S. created an opportunity for hemp-derived cannabidiol (CBD) products in retail and pharmaceutical channels. Also, many countries, including Canada, China, Italy, Australia, and South Korea, have legalized hemp for growth and export. In the United States, CBD is widely available from retailers, including online, drug and convenience stores, natural products, beauty, grocery, and pet stores. According to the Grand View Research Industrial Hemp Market Analysis, the global CBD market was valued at $4.6 billion in 2018 and is expected to grow at a CAGR of 22.2% from 2019 to 2025. Additionally, the global industrial hemp market size was estimated at $4.71 billion in 2019 and is expected to show a revenue-based compound annual growth rate of 15.8%.Generally

A recent CBS News poll found that 88% of Americans support the legal use of medical cannabis when recommended by a doctor. Cannabis Business Daily projects sales in the cannabis industry to be $15.5 billion and $20.3 billion in 2020 and 2021, respectively, and sales could be as high as $37 billion in 2024. The size of the industry was only $3.4 billion ~~industry~~ in 2015. Sharp sales increases in recently launched medical cannabis programs – as well as continued gains in adult-use markets – are expected to fuel much of the industry’s growth over the coming years.

2Forty U.S. states, the District of Columbia, Puerto Rico and Guam have legalized some form of whole-plant cannabis cultivation, sales and use for certain medical purposes. Eighteen of those states, the District of Columbia and Northern Mariana Islands have also legalized cannabis for adults for non-medical purposes (sometimes referred to as adult use). Under federal law, however, those activities are illegal. Cannabis, other than hemp (defined by the U.S. government as Cannabis Sativa L., with a THC concentration of not more than 0.3% on a dry weight basis), is a Schedule I controlled substance under the Controlled Substances Act (the “CSA”). Even in states or territories that have legalized cannabis to some extent, the cultivation, possession, and sale of cannabis, whether in-state or interstate, violate the CSA and are punishable by imprisonment, substantial fines and forfeiture. Moreover, individuals and entities may violate federal law if they aid and abet another in violating the CSA or conspire with another to violate the law. Violation of the CSA is a predicate for the violation of other criminal laws, including money laundering laws and the Racketeer Influenced and Corrupt Organizations Act. The U.S. Supreme Court has ruled that the federal government has the authority to regulate and criminalize the sale, possession and use of cannabis, even for individual medical purposes, regardless of whether it is legal under state law.

Thirty-nine U.S. states, the District of Columbia, Puerto Rico and Guam have legalized some form of whole-plant cannabis cultivation, sales and use for certain medical purposes. Eighteen of those states and the District of Columbia and Northern Mariana have also legalized cannabis for adults for non-medical purposes (sometimes referred to as adult use). Under federal law, however, those activities are illegal. Cannabis, other than hemp (defined by the U.S. government as Cannabis sativa L. with a THC concentration of not more than 0.3% on a dry weight basis), is a Schedule I controlled substance under the CSA. Even in states or territories that have legalized cannabis to some extent, the cultivation, possession, and sale of cannabis, whether in-state or interstate, violate the CSA and are punishable by imprisonment, substantial fines and forfeiture. Moreover, individuals and entities may violate federal law if they aid and abet another in violating the CSA or conspire with another to violate the law. Violation of the CSA is a predicate for violation of other criminal laws, including money laundering laws and RICO. The U.S. Supreme Court has ruled that the federal government has the authority to regulate and criminalize the sale, possession and use of cannabis, even for individual medical purposes, regardless of whether it is legal under state law.

While the U.S. government has not enforced these laws against companies complying with state cannabis laws, it retains the authority to do so, and therefore, the likelihood of any future adverse enforcement against companies complying with state cannabis laws remains uncertain. U.S. Attorneys can prosecute violations of the CSA, including cannabis activities that comply with state law; however, U.S. Attorneys have not targeted state-law-compliant entities in recent years. The policy of not prosecuting such entities has continued under current U.S. Attorney General Merrick Garland.

Since 2014, versions of the U.S. omnibus spending bill have included provisions prohibiting the DOJ, which includes the DEA, from using appropriated funds to prevent states from implementing their medical-use cannabis laws. In 2016, the U.S. Court of Appeals for the Ninth Circuit held that this provision prohibits the DOJ from spending funds to prosecute individuals who engage in conduct permitted by state medical-use cannabis laws and who strictly comply with such laws and other courts that have considered the issue have ruled similarly. However, the court noted that if these provisions were not continued, prosecutors could prosecute conduct that occurred even while the provision was previously in force. This decision does not apply to adult-use businesses.2

~~Despite~~Since ~~the~~2014, ~~ongoing~~versions ~~federal illegality~~ of ~~cannabis,~~ the U.S. ~~DEA~~omnibus ~~has~~spending ~~authorized~~bill ~~certain~~have ~~institutions~~included toprovisions ~~conduct~~that ~~research~~prohibit ~~using~~the ~~cannabis.~~Department ~~Between~~of ~~January~~Justice ~~2017~~(the ~~and January 2019~~“DOJ”, including the ~~DEA’s~~Drug Enforcement ~~projections~~Administration ~~for~~(the ~~federally~~“DEA”), ~~approved~~from ~~cannabis~~using ~~research~~appropriated ~~projects~~funds ~~increased~~to ~~dramatically:~~prevent ~~the~~states ~~number~~from ofimplementing ~~federally~~their ~~registered~~medical-use cannabis ~~researchers increased from 384 to 542~~laws. In ~~2019~~2016, the ~~DEA~~U.S. ~~announced~~Court ~~that~~of itAppeals ~~would~~for ~~further~~the ~~facilitate~~Ninth ~~and~~Circuit ~~expand~~held ~~scientific~~that ~~and medical~~this ~~research~~provision ~~for~~prohibits ~~cannabis in~~ the ~~United~~DOJ ~~States,~~from ~~including~~spending ~~registering additional entities~~ funds to ~~produce~~prosecute ~~cannabis~~individuals ~~for~~who ~~researchers~~engage ~~and increasing~~in ~~the~~conduct ~~amount~~permitted ~~and~~by ~~variety~~state ofmedical-use cannabis ~~available~~laws ~~for~~and ~~research~~who instrictly ~~order~~comply towith ~~“facilitate~~such ~~research,~~laws ~~advance scientific understanding~~and ~~about~~other ~~the~~courts ~~effects~~that ofhave ~~marijuana,~~considered ~~and potentially aid in~~ the ~~development~~issue ofhave ~~safe~~ruled ~~and~~similarly. ~~effective~~However, ~~drug~~the ~~products~~court noted that ~~may~~if bethese ~~approved~~provisions ~~for~~were ~~marketing by~~not ~~the Food and Drug Administration.” Further~~continued, prosecutors ~~this~~could ~~announcement~~prosecute ~~acknowledged~~conduct ~~the possibility~~ that ~~medical~~occurred ~~cannabis~~even orwhile ~~related products may, in~~ the ~~future,~~provision ~~require~~was ~~FDA~~previously ~~approval~~in ~~and~~force. ~~come~~This ~~under~~decision ~~the~~does ~~FDA’s~~not ~~FDCA~~apply ~~jurisdiction~~to adult-use businesses.

Despite the ongoing federal illegality of cannabis, the DEA has authorized certain institutions to conduct research using cannabis. Between January 2017 and January 2019, the DEA’s projections for federally approved cannabis research projects increased dramatically: the number of federally registered cannabis researchers increased from 384 to 542. In 2019, the DEA announced that it would further facilitate and expand scientific and medical research for cannabis in the United States, including registering additional entities to produce cannabis for researchers and increasing the amount and variety of cannabis available for research to “facilitate research, advance scientific understanding about the effects of marijuana, and potentially aid in the development of safe and effective drug products that may be approved for marketing by the Food and Drug Administration.” Further, this announcement acknowledged the possibility that medical cannabis or related products may, in the future, require FDA approval and come under the FDA’s FDCA jurisdiction.

On December 18, 2020, the DEA finalized regulations pertaining to applications by entities seeking to become registered with the DEA to grow cannabis as bulk manufacturers for authorized purposes. Under these and other applicable regulations, applicants are responsible for demonstrating that they have met various requirements, including requirements to possess appropriate state authority, document that their customers are licensed to perform research, and employ adequate safeguards to prevent diversion.

On May 14, 2021, the DEA announced that memorandums of agreement were provided to an unspecified and unnamed number of companies to collaborate with the DEA “to facilitate the production, storage, packaging, and distribution of marijuana under the new regulations as well as other applicable legal standards and relevant laws.” To the extent these memorandums of agreement are finalized, DEA anticipates issuing DEA registrations to these manufacturers. Each applicant will then be authorized to cultivate cannabis – up to an allotted quota – in support of the more than 575 DEA-licensed researchers nationwide. As of 2022, six companies have been granted DEA registrations to bulk-manufacture cannabis.

If the DEA continues the above policies and activities (as to which no assurance can be given), the Company believes that demand for medical cannabis, and in turn, the Company’s products and services, will increase.

~~According~~As todiscussed under the ~~Biden~~caption ~~campaign website:~~ “~~A Biden~~Alpha ~~Administration will support the legalization of cannabis for medical purposes and reschedule cannabis as a CSA Schedule II drug~~Research soBusiness,” ~~researchers~~recent ~~can~~legislation ~~study~~has ~~its~~made ~~positive and negative impacts. This will include allowing the V.A. to~~ research ~~the~~in ~~use~~product ofcandidates ~~medical~~containing ~~cannabis to treat veteran~~hemp-~~specific~~derived ~~health~~cannabinoids ~~needs.”~~possible ~~Neither~~without ~~the Republican nor the Democrat party platform for the 2024 election takes a position~~FDA ~~on the legalization or decriminalization of cannabis~~approval.

As discussed under the caption “Alpha Research Business,” recent legislation has made research in product candidates containing hemp-derived cannabinoids possible without FDA approvals.

The Company believes that the anticipated growth of the cannabis industry, propelled in significant part by the increasing legalization of cannabis, offers the Company opportunities to expand. The industry requires skilled and educated cannabis professionals to operate.

~~Overview~~CBD ~~of the Pharmacology University Business~~Products

~~Through~~Until ~~the~~2014, ~~Pharmacology~~when 7 U.S. Code ~~University~~§5940 ~~Business,~~became ~~the~~federal ~~Company~~law ~~provides~~as ~~knowledge~~part ~~and~~of ~~promotes~~the ~~professionalism~~Agricultural inAct of 2014 (the ~~rapidly~~“2014 ~~growing~~Farm ~~worldwide~~Act”), ~~cannabis~~products ~~industry~~containing ~~through~~oils derived ~~education~~from inhemp, ~~and~~notwithstanding ~~research~~a ~~about~~minimal or no THC content, were classified under the ~~medical~~CSA ~~properties~~Controlled ~~and~~Substances ~~healing~~Act ~~virtues~~(the of“CSA”), as ~~this~~Schedule ~~substance~~I illegal drugs. The ~~Company~~2014 ~~does~~Farm ~~not~~Act ~~cultivate~~expired on September 30, ~~sell~~2018, orand was replaced by the Agricultural Improvement Act of ~~distribute~~2018 ~~cannabis~~on orDecember ~~cannabis-infused~~20, ~~products~~2018 ~~and~~(the ~~has~~“2018 noFarm ~~plans~~Act to“), dowhich soremoved hemp, defined as cannabis with less than 0.3% ~~Pharmacology~~of ~~University~~THC, isfrom Schedule ~~not~~1 anstatus ~~institution~~under the CSA and legalized the cultivation and sale of ~~higher~~hemp ~~education~~at the federal level, subject to compliance with certain isfederal ~~not~~requirements ~~chartered,~~and ~~regulated~~state orlaw, ~~accredited~~among byother ~~any~~things. ~~governmental~~THC oris ~~private~~the ~~agency~~psychoactive ~~and~~component ~~does~~of ~~not~~plants ~~offer~~in ~~training~~the ~~that~~cannabis ~~qualifies~~family, ~~recipients~~generally toidentified ~~become~~as ~~pharmacists~~marihuana or ~~pharmacologists~~marijuana.

The ~~Pharmacology~~2018 ~~University Business~~Farm ~~and~~Bill ~~its~~also ~~prospects~~shifted ~~depend~~regulatory onauthority from the ~~growth~~Drug ofEnforcement ~~the~~Administration ~~cannabis~~to ~~industry and~~ the ~~need~~Department ~~for~~of ~~experienced,~~Agriculture. ~~educated~~The ~~professional~~2018 ~~persons~~Farm ~~to lead~~Bill ~~and~~did ~~grow~~not ~~that~~change ~~industry ethically and responsibly in~~ the United States Food and Drug ~~other countries where the Company~~Administration’s ~~activities~~(“FDA”) ~~are legal.~~oversight ~~While~~authority ~~the~~over ~~Company~~CBD ~~embraces~~products. ~~the~~The ~~legal~~2018 ~~cannabis~~Farm ~~industry~~Act ~~generally,~~delegated ~~its~~the ~~primary~~authority ~~focus~~to isthe states onto ~~educating~~regulate ~~cannabis industry workers~~ and ~~leaders~~ ~~and~~limit ~~scientific~~the ~~research~~production ~~and development~~ of hemp and ~~cannabis~~hemp-derived ~~for~~products ~~medicinal~~within ~~and~~their ~~commercial applications~~territories. ~~One~~As of the ~~Company’s most~~date ~~important~~of ~~assets~~this isreport, 44 ~~the~~states ~~close~~have ~~relationship~~adopted oflaws ~~its personnel to~~ and ~~cooperation~~regulations ~~with~~that ~~law~~fully ~~enforcement~~or ~~agencies~~partially inlegalize the ~~locations~~production ~~where it~~and ~~does~~sale ~~business.~~of ~~Police~~hemp ~~agencies~~and inhemp-derived ~~several countries have appeared as guest speakers at the Company’s cannabis seminars~~products.

In the United States, the Company has conducted instructional seminars and cannabis classes in the states of Texas, Arkansas, Florida, Illinois, Missouri, Oklahoma and Georgia, as well as Puerto Rico, and is planning to do likewise in the remaining states. Currently, the Company is holding seminars and classes only in the State of Texas. The Company has conducted instructional seminars and cannabis classes in Mexico, Peru, Ecuador, Colombia and the Dominican Republic. With the COVID-19 pandemic having abated, it plans to resume these activities in Mexico, Peru, Ecuador and the Dominican Republic and to expand into Argentina, Chile, Brazil, Panama and other Latin American countries where its activities are lawful. As stated below, however, the Company believes that the demand for its educational products is towards online education and away from classrooms and seminars.3

~~Before~~The ~~the~~FDA ~~pandemic,~~has ~~the Company~~indicated ~~offered~~that, ~~and~~in ~~with~~its ~~the~~view, ~~abatement~~certain products ofcontaining ~~the~~CBD ~~pandemic,~~may isnot ~~offering,~~be ~~opportunities~~lawful ~~for~~under ~~learning~~the Federal Food, ~~discovery~~Drug and ~~engagement~~Cosmetic toAct ~~students, doctors,~~(“FDCA”). ~~scientists,~~On ~~entrepreneurs~~December ~~and~~20, ~~others~~2018, inafter the apassage ~~real-world~~of ~~setting.~~the ~~The~~2018 ~~Company~~Farm ~~offers~~Bill, aFDA ~~full~~Commissioner ~~range~~Scott ofGottlieb ~~educational~~issued ~~programs~~a atstatement ~~all levels~~in ~~and~~which ~~pursues~~he areiterated ~~broad~~the ~~agenda~~FDA’s ofposition that ~~research,~~the ~~innovative~~FDA ~~and~~requires ~~creative~~that ~~activities~~a ~~and~~cannabis ~~builds~~product ~~partnerships~~(hemp-derived ~~with~~or ~~other~~otherwise) ~~educational~~that ~~institutions, community~~is ~~organizations,~~marketed ~~government~~with ~~agencies~~a ~~and~~claim ~~the~~of ~~private~~therapeutic ~~sector~~benefit inor ~~many~~with any ~~jurisdictions,~~other ~~including~~claim ~~Jorge~~with ~~Tadeo~~respect ~~Lozano~~to ~~University~~disease ~~in Bogota,~~to ~~Cartagena,~~be ~~and~~approved ~~Santa~~by ~~Marta,~~the ~~Colombia;~~FDA ~~Clayton~~for ~~State~~its ~~University,~~intended ~~Atlanta,~~use ~~Georgia;~~before ~~Autonomous~~it ~~University~~may ofbe ~~Santo~~introduced ~~Domingo,~~into ~~Dominican~~interstate commerce ~~Republic;~~and ~~EUFLORIA~~that ~~Medical~~the ~~Cannabis~~FDCA ~~Dispensary,~~prohibits ~~Tulsa,~~introducing ~~Oklahoma;~~into ~~the~~interstate ~~Polytechnic~~commerce ~~University~~food ofproducts ~~Puerto~~containing ~~Rico~~added inCBD, ~~San~~and ~~Juan,~~marketing ~~Dispensarios~~products ~~420,~~containing ~~Puerto~~CBD ~~Rico;~~as ~~Cannapolis~~a ~~Scientific~~dietary ~~Farm~~supplement, inregardless ~~Colombia;~~of ~~Hemp~~whether ~~Ecuador~~the insubstances ~~Ecuador~~are hemp-derived.

State Regulation

Texas

In 2015, Texas adopted the Texas Compassionate Use Act (the “TCUP”), which permitted the use of cannabis products with low levels of THC for patients who suffered from intractable epilepsy. The TCUP was amended in 2019, 2021, and 2025 to include several other conditions, including cancer, autism and chronic pain, that could be treated by THC products and increase the permissible level of THC.

The Texas legislature recently passed, and Governor Greg Abbott approved Law HB 46 (“Law HB 46”), which expands and enhances the TCUP. The changes made by HB 46 include:

Adding the following qualifying conditions to those set forth in the TCUP: chronic pain (continuous or intermittent severe pain for more than 90 days), Crohn’s disease, traumatic brain injury, terminal illnesses, and being in hospice care.

Adding methods of delivery, including lotions, patches, suppositories, and non-smoked pulmonary inhalation.

Replacing the limit of 1% THC by weight under the TCUP with a level of up to 10 milligrams per dose and a package not to exceed 1 gram of THC.

Making recommendations effective for one year with four 90-day refills.

Directing the Department of Public Safety to issue 12 additional licenses for dispensing organizations, for a total of 15, and requiring a dispensing organization to become operational within 24 months after its license is issued.

Requiring monitoring of dispensed cannabis by the Texas Board of Pharmacy via the Prescription Monitoring Program.

Requiring that a person owning 10% or more in a dispensing organization submit his fingerprints for a background check.

Requiring that patient information held by a registry be kept confidential.

Other States

CBD products are legal in 24 states and partially legal in 20 others. Because the Company plans to manufacture and sell VitaCookies only within the State of Texas for the time being, the Company has not analyzed the laws of the other states with respect to the legality of its CBD products, but will do so before marketing its CBD products therein.

Pharmacology University Business

Overview of the Pharmacology University Business

Through the Pharmacology University Business, the Company provides knowledge and promotes professionalism in the rapidly growing cannabis industry through education in and research about the medical properties and healing virtues of this substance. The Company does not cultivate, sell or distribute cannabis or cannabis-infused products and has no plans to do so. Pharmacology University is not an institution of higher education, is not chartered, regulated or accredited by any governmental or private agency and does not offer training that qualifies recipients to become pharmacists or pharmacologists.

Pharmacology University’s business and prospects are influenced by the growth of the cannabis industry and by the demand for experienced, educated professionals to guide and expand that industry ethically and responsibly in the United States and other countries where the Company may operate legally. While the Company supports the legal cannabis industry generally, its primary focus is on educating cannabis industry workers and leaders, as well as conducting scientific research and development of hemp and cannabis for medicinal and commercial applications. One of the Company’s most important assets is the close relationship of its personnel with, and cooperation from, law enforcement agencies in the jurisdictions where it does business. Police agencies in several countries have participated as guest speakers at the Company’s seminars.

In the United States, the Company has conducted instructional seminars and cannabis classes in Texas, Arkansas, Florida, Illinois, Missouri, Oklahoma, and Georgia, as well as in Puerto Rico, and intends to expand to additional states where legally permissible. Currently, seminars and classes are being held only in Texas. The Company has also conducted instructional seminars and cannabis classes in Mexico, Peru, Ecuador, Colombia, and the Dominican Republic. At present, the Company is resuming and expanding its in-person educational programs for business leaders, physicians, attorneys, nurses, insurance agents, patients, and others regarding medical cannabis programs. In Texas, particular attention is given to the Texas Compassionate Use Program (TCUP), established in 2015, and expanded by House Bill 46, with regard to which the Company is planning to provide education and support.

The Company offers opportunities for learning, discovery and engagement to students, doctors, scientists, entrepreneurs and others in a real-world setting. It provides a full range of educational programs at all levels and pursues a broad agenda of research, innovative and creative activities and builds partnerships with academic institutions, community organizations, government agencies and the private sector in many jurisdictions, including Jorge Tadeo Lozano University in Bogota, Cartagena, and Santa Marta, Colombia; Clayton State University, Atlanta, Georgia; Autonomous University of Santo Domingo, Dominican Republic; EUFLORIA Medical Cannabis Dispensary, Tulsa, Oklahoma; the Polytechnic University of Puerto Rico in San Juan, Dispensarios 420, Puerto Rico; Cannapolis Scientific Farm in Colombia; Hemp Ecuador in Ecuador.

Educational Services

The Company offers multilevel educational services to entrepreneurs, medical and legal professionals, cultivators, dispensary technicians, manufacturers, patients and others who desire to participate in the cannabis industry or who are otherwise interested in cannabis. These services include:

	·	Continuing medical education courses for physicians

	·	Continuing legal education courses for attorneys

	·	Certification courses for physicians

	·	Certification for industry workers

	·	General education seminars

	·	On-site training

These courses cover all aspects of the medical cannabis industry. For the general public, they focus on the history of cannabis, its medicinal value, dispensary concepts, legal issues and ethics, production, growing and extracts, security, operations and economics. For doctors, our courses and seminars cover subjects such as medicinal uses of cannabis, the biochemistry of cannabis, functions of the endocannabinoid system, pharmacology, cannabis use and abuse, and administration and dosage of cannabis medications. The cultivation course focuses on germination, cultivation practices, cloning, growth stages and harvesting, drying and curing, and the manufacturing course covers the chemical composition of cannabis plants, extraction of oils, laboratory practices, the manufacture of cannabis products and marketing. Overall, we have certified and graduated several thousand students in our courses in the United States, Puerto Rico and Colombia.

Courses are taught and seminars are led by degreed professionals, university professors, and industry experts with at least two years of commercial experience in the particular subject. For example, the cultivation course might be taught by a professor of horticulture, an individual with an M.S. degree in agriculture, or a master grower with three years’ experience growing crops of at least 500 plants. ~~Before~~The ~~the~~Company ~~COVID-19~~has ~~pandemic,~~held classes ~~were usually held~~ at ~~local~~ colleges and universities in classrooms with projectors, screens and microphones., ~~Among~~including ~~these~~at ~~colleges and universities were~~ the University of Texas, Houston; Texas Women’s University; University of Oklahoma; Oklahoma State University; Clayton State University, Atlanta; Polytechnic University, San Juan; Texas A&M University; and Jorge Tadeo Lozano University in Bogota, Cartagena, and Santa Marta, Colombia. The Company believes, however, that due to ~~the COVID-19 pandemic, which resulted in the closing of classroom and seminar education, as well as~~ convenience, demand for its courses is trending towards online education and away from classrooms and seminars.

~~Students~~The ~~learn~~Company ~~about~~plans ~~Pharmacology University~~to ~~through~~conduct ~~its website~~seminars, ~~social media~~courses, ~~ticket venues,~~ and ~~local~~training ~~cannabis~~programs ~~groups.~~that ~~Upon~~will ~~completing~~support aphysicians, ~~course of study~~attorneys, ~~students receive certificates of completion~~chemists, ~~which are not certifications of their ability to work in a particular field~~biologists, ~~but recognition of their completion of a non-accredited class. A 130-hour course lasting a semester was available at the University of Tadeo in Colombia~~insurers, ~~and the students who completed it received a certificate entitled “Diplomado en Cannabis.” In addition~~dietitians, ~~CME~~ and ~~CLE~~veterinarians ~~credits~~in ~~were available~~understanding ~~for~~this ~~doctors~~new ~~and~~regulatory ~~lawyers~~framework ~~taking~~created ~~the~~by ~~classes~~HB 46. The ~~Company~~first ~~received~~of ~~CLE~~these ~~approvals~~will ~~for~~be ~~courses~~a ~~that~~seminar iton ~~offered~~November in1, ~~Arkansas~~2025, ~~(Office~~at ofUTHealth ~~Professional Programs)~~Houston, ~~Oklahoma~~with ~~(Oklahoma MCLE Commission)~~ CLE and ~~Texas (State Bar of Texas) and received~~ CME ~~approvals~~accreditation. ~~for courses that it has offered in Arkansas (University of Arkansas for Medical Sciences Office of Continuing Education)~~Subsequently, ~~Texas and Florida (Ponce Medical School Foundation). We were~~ the ~~first~~Company ~~company~~plans ~~approved~~to byhold ~~the~~five ~~Department~~seminars ofin ~~Health of the Commonwealth of Puerto Rico as a provider of all training certificates~~Houston, ~~including~~ ~~medical education~~Dallas, ~~agriculture~~San ~~and manufacturing education~~Antonio, ~~dispensary~~El ~~education,~~Paso and ~~others in the medicinal cannabis industry~~Brownsville.

5Students learn about Pharmacology University through its website, social media, ticket venues, and local cannabis groups. Upon completing a course of study, students receive certificates of completion, which are not certifications of their ability to work in a particular field, but recognition of their completion of a non-accredited class. A 130-hour course lasting a semester was available at the University of Tadeo in Colombia, and the students who completed it received a certificate entitled “Diplomado en Cannabis.” In addition, CME and CLE credits were available for doctors and lawyers taking the classes. The Company received CLE approvals for courses that it offered in Arkansas (Office of Professional Programs), Oklahoma (Oklahoma MCLE Commission) and Texas (State Bar of Texas) and received CME approvals for courses that it has offered in Arkansas (University of Arkansas for Medical Sciences Office of Continuing Education), Texas and Florida (Ponce Medical School Foundation). We were the first company approved by the Department of Health of the Commonwealth of Puerto Rico to provide all training certificates, including medical education, agriculture and manufacturing education, dispensary education, and others in the medicinal cannabis industry.

After the advent of the COVID-19 pandemic, all of our classrooms and seminars venues were forced to close. We also canceled all travel plans to further our expansion. To meet this pandemic, we created online courses. We currently have more than 100 videos available online in English, Spanish, Portuguese, Italian and Arabic and we plan to add other languages. Additionally, we have used Zoom to hold virtual classes to teach students and be able to respond to their questions in real time during the courses. However, revenue received from online courses has not replaced the revenue that we believe we would have generated if our classrooms and public venues had remained open. With the abatement of the COVID-19 pandemic, the Company is attempting to resume teaching in classrooms and public forums. A result of the closing of classrooms due to the pandemic was increasing reliance on online classes. The Company believes that this trend will increase due to the ease of attendance and the ability of students to learn at times that are convenient to them. The Company believes that teaching in classrooms and public forums is unlikely to resume to its former extent.6

The Company ~~believes~~is ~~that~~resuming ~~teaching~~and expanding its in-person ~~classrooms~~classroom teaching and ~~public~~seminars, ~~forums~~while iscontinuing ~~unlikely~~ to ~~resume~~develop online courses to ~~its~~provide ~~former~~flexible ~~extent.~~and Weconvenient ~~held~~learning ~~two~~opportunities for ~~classes~~students ~~and~~in nomultiple ~~seminars~~languages. ~~during~~Currently, ~~the~~it ~~year~~has ~~ending May~~more ~~31,~~than ~~2024,~~100 ~~producing~~videos ~~revenue~~available ofonline ~~$23~~in English,~~006~~ Spanish, ~~compared~~Portuguese, ~~with~~Italian, Arabic, ~~three~~French, and Mandarin. Virtual classes ~~and~~are noalso ~~seminars,~~designed ~~producing~~to ~~revenues~~be ofconducted ~~$52~~via Zoom,~~315~~ allowing students to interact in ~~the~~real ~~year~~time and ~~ended~~ask ~~May~~questions ~~31,~~during ~~2023~~the courses. AsThe aCompany ~~result~~expects that online courses may provide revenue as these activities expand. In addition, both wein-person and online programs are ~~concentrating~~expected onto ~~expanding~~grow. ~~our~~The ~~online~~Company continues to broaden its offerings to business leaders, medical and legal professionals, and other stakeholders in the cannabis industry.

The Company believes that teaching in classrooms and public forums is unlikely to resume to its former extent. We held no classes or seminars during the year ending May 31, 2025, producing revenue of $0, compared with two classes and no seminars during the year ending May 31, 2024, producing revenue of $6,335.

Digital Products

~~As a result of the COVID-19 pandemic, which made classroom and seminar education impossible,~~ Pharmacology University ~~focused~~offers ~~on the production of~~ educational materials for sale on online platforms, (including those operated by Amazon, Zinio, Apple, ~~Walmart/~~Kobo, Barnes & Noble, and Google Books). However, the trend of students’ preference for online courses has adversely affected the demand for classroom teaching and seminars. The Company does not expect that demand for teaching in these venues will return to pre-pandemic levels. It also focuses on entering into subscription and commercial agreements with universities and e-commerce platforms.

WeThe ~~have~~Company has published 50 cannabis-related eBooks in five languages, ~~have~~ produced videos tofor ~~offer~~ online distribution, and ~~have~~ recorded over 13,000 minutes of audio in 5five languages. WeArtificial intelligence services have also been engaged ~~artificial~~ ~~intelligence services~~ to generate translations of these materials in up to 100 additional languages. ~~This~~These ~~activity~~activities have ~~has~~ resulted in increased ~~expenses~~expense, ~~while~~with ~~producing~~ minimal revenue and no profit to date; however, wethe ~~believe~~Company expects that itthey ~~will~~may become profitable and berepresent a ~~significant~~ growing component of ~~our~~its business.

WeThe ~~have~~Company ~~aimed~~publishes toits ~~publish our~~ educational content on ~~different~~various marketplaces that host products in languages commonly used worldwide. WePlatforms ~~work~~include ~~with~~those ~~platforms~~ from Brazil, Spain, England, Mexico, Canada, the United States, Germany, and other countries. WeCurrently, ~~currently~~the ~~have~~Company ~~four~~has three types of products published onacross ~~different~~ these platforms.:

· E-Books: WeThe ~~publish~~Company publishes fifty titles in Spanish, English, Portuguese, Italian, and Arabic on Amazon, Kobo, and Google Books. In addition, Smashwords distributes ~~our~~its content on Barnes & Noble, Apple, Baker & Taylor’s Axis 360, OverDrive, Scribd, cloudLibrary, Gardners Extended Retail, Odilo, and Gardners Library. · Audiobooks: Findawayvoices distributes our content on 3Leaf Group, Axiell, Baker & Taylor, Bibliotheca, Bidi, EBSCO, Follett, hoopla, LOL, Dilo, Overdrive, Perma-Bound, Ulverscroft and Wheelers, as well as on 24symbols, Anyplay, Apple, Audiobooks.com, AudiobooksNow, AudiobooksNZ, BajaL, BingeBooks, Bokus Play, Bookmate, Chirp, Cliq, Downpour, eStories, Google Play, Hummingbird, Instaread, Leamos, Libro.FM, Milkbox, Nextory, NOOK, Scribd, and Ubook. · Video courses: We publish 161 titles on Amazon (6 courses), Sympla (17 courses), Teachlr (62 courses), Edusity (13 courses), Simplivlearning (16 courses), Alugha (40 courses), Aprendum (4 courses), and Unihance (105 courses).

Audiobooks: Findawayvoices distributes the Company’s content on 3Leaf Group, Axiell, Baker & Taylor, Bibliotheca, Bidi, EBSCO, Follett, hoopla, LOL, Dilo, Overdrive, Perma-Bound, Ulverscroft, and Wheelers, as well as on 24symbols, Anyplay, Apple, Audiobooks.com, AudiobooksNow, AudiobooksNZ, BajaL, BingeBooks, Bokus Play, Bookmate, Chirp, Cliq, Downpour, eStories, Google Play, Hummingbird, Instaread, Leamos, Libro.FM, Milkbox, Nextory, NOOK, Scribd, and Ubook.

Video Courses: The Company publishes 161 titles on Amazon (6 courses), Sympla (17 courses), Teachlr (62 courses), Edusity (13 courses), Simplivlearning (16 courses), Alugha (40 courses), Aprendum (4 courses), and Unihance (105 courses).

We published Cannabis Worlds, a digital magazine, on Google Books, Zinio, Pocketmags and Magzter. In April 2024, we ceased publication.

The Company believes that the amount and scope of its digital products exceed those offered by any of its competitors in cannabis-related education.

A staff of 14 independent contractors in Venezuela, Argentina, Colombia, Brazil and Texas holds classes; researches and edits materials; translates materials; prepares audio-visual materials; and engages in web development.

Franchising

~~Until~~The ~~the~~Company ~~COVID-19 pandemic, we~~ offered educational programs to franchisees worldwide. A franchisee purchased the right to provide our courses in its particular city. In addition to an initial franchise fee, a franchisee paid a 10% franchise fee and a 2% advertising fee on all gross sales. We assisted in creating and registering a franchisee’s business identity; developing and activating its websites; creating its social media platforms; providing it with marketing plans; assisting in finding venues for their classes; explaining how to find qualified instructors; providing PowerPoint presentations as well as books for students and instructors; and providing one week of one-on-one training relating to the operation of the franchise. In addition, we provided one month of marketing assistance. As a result of the pandemic, we received no revenue from these franchisees in the year ended May 31, 2023. After the COVID-19 pandemic abated, we attempted to resume franchise operations, but have been unable to find customers and received no revenue from franchising in the year ended May 32, 2024.. In April 2024, we decided not to pursue franchising.

Consulting

~~Prior~~The ~~to the pandemic, the~~ Company offered consulting services, which included: These services included:

· creating and presenting advertising material for campaigns in traditional and digital media, including publicity strategy, campaign creation, design of flyers, advertising social networks, newspapers and magazines and creation of audiovisual content. · consulting services to entrepreneurs ~~who are~~ considering entering the cannabis industry, manufacturers and growers, including preparation of business plans, guidance in business structure, guidance in seeking investment, preparation of license and other applications and development of operating procedures.

The costs of these services were based on the nature of each assignment.

The Company provided these services in many states and Puerto Rico and assisted in obtaining over 40 licenses for its clients for dispensaries, cultivation, manufacturing and a full analytical laboratory.

InFor the ~~year~~years ended May 31, ~~2023~~2024, ~~the~~and ~~Company~~May ~~began~~31, to2025, ~~offer~~the ~~these~~Company ~~services again and~~ recorded ~~revenue~~revenues of $828,~~333~~641 ~~for that year~~ and $0, ~~for~~respectively, ~~the~~from ~~year~~consulting ~~ended~~services. ~~May 31~~However, ~~2024.~~in WeSeptember ~~are~~2025, ~~determining~~the Company ~~whether~~entered weinto ~~will~~an ~~continue~~agreement ~~this~~to ~~operation~~provide advisory services for obtaining a hemp license.

Alpha Research Business

Through the Alpha Research Business, based in Houston, Texas, the Company offers specialized services in all therapeutic areas of clinical trials and has conducted over 20 clinical trials for Sponsors and CROs. These trials have included drugs relating to diseases in the areas of asthma, allergies, renal disorders, neurology disorders, cardiac and vascular disorders, nutrition/metabolism, obstetrics/gynecology, dermatology, oncology, ophthalmology, orthopedics, gastroenterology, psychiatric disorders, infectious diseases, pulmonary and respiratory diseases, urology and COVID-19, as well as devices for orthopedic and cardiovascular problems. Our clients have included Sponsors such as Pfizer Inc., Merck & Co., Inc., Shionogi & Co., Ltd., Medtronic plc, Novartis, GlaxoSmithKline plc, Gilead Sciences, Inc. and Johnson & Johnson, and CROs, such as PPD, Inc., Icon plc, Parexel, PRA Health Sciences, Inc., Covance, IQVIA Holdings Inc. and Medpace Holdings, Inc. In the near future, Alpha Research intends to conduct cannabinoid clinical trials, in which it will be the Sponsor. One of our clients is Vita Biotech Research, LLC (“Vita”), which is engaged in data collection for clinical trials. For information regarding the interest of two of our officers and directors in Vita, see “Certain Relationships and Related Party Transactions – Vita Agreement.”

7Clinical trials are a research method designed to evaluate and test new drugs or devices. They are typically conducted in four phases, each of which has a different purpose and helps scientists to answer various questions.

Clinical trials are a research method designed to evaluate and test new drugs or devices. They are typically conducted in four phases, each of which has a different purpose and helps scientists answer different questions.

	·	Phase I. Researchers test an experimental drug or treatment in a small group of people for the first time. The researchers evaluate the treatment’s safety, determine a safe dosage range, and identify side effects.

	·	Phase II. The experimental drug or treatment is given to a larger group of people to ascertain whether it is effective and to evaluate its safety further.

	·	Phase III. The experimental study drug or treatment is administered to large groups of people. Researchers confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug or treatment to be used safely.

	·	Phase IV. Post-marketing studies, which are conducted after a treatment is approved for use by the FDA, provide additional information, including information relating to treatment, risks, benefits and best use.

The Company’s facilities are equipped with examination and blood drawing rooms, storage for investigational medication and study-related equipment. The Company employs only clinical research coordinators (“CRCs”) with at least five years of experience. CRCs are involved in supervising drug trials and medical research, which involves recruiting patients for medical and drug trials and screening them to ensure that they meet the guidelines of the trial, as well as following good clinical practice, overseeing the progress of the clinical trial and ensuring that it is properly conducted, recorded, and reported.

The recruitment of subjects from minority, rural and economically disadvantaged groups is important to clinical trials because the benefits and risks of new drugs with respect to them may differ from other groups due to genetic, environmental and other factors. To enhance such recruitment, the Company has worked with community organizations, churches, social services and public agencies and has provided transportation services.

The Alpha Research Business is staffed by seven personnel responsible for regulatory and Investigational Review Board (“IRB”) processes and a staff of two auditors. An IRB is an independent body required by federal regulation, comprising medical, scientific, and nonscientific members, ~~the~~ ~~responsibility~~whose ~~of which~~ responsibility is to ensure the protection of the rights, safety, and well-being of human subjects involved in a clinical trial. An IRB reviews and approves clinical trials, protocols, amendments, methods and materials to be used in obtaining and documenting informed consents from trial subjects.

We have more than six principal investigators, who are physicians who prepare and perform or oversee clinical trials, usually in conjunction with their medical practices. These investigators are independent contractors. In addition, we have seven professional personnel who analyze data and report the results of trials to Sponsors and CROs, all of whom are independent contractors; they are encouraged to keep up to date on good clinical practices and regulations relating to clinical research and a part-time accountant.

Clinical Trials for Sponsors and CROs

In connection with these clinical trials, the Company will contract with a Sponsor or CRO to provide services in connection with a clinical trial after it has provided information respecting its ability to provide them and after a visit by the Sponsor or CRO to our facilities to confirm our ability to conduct the trial and to establish communications procedures. After further measures, which include establishing a budget and providing additional information about the Company and a second visit to our facilities, we will enter into a contract with the Sponsor or CRO, which will issue a “Site Activation Letter.” When we receive this letter, we begin enrolling volunteer test subjects.

Alpha Research finds Sponsors and CROs in three ways:

· Recruitment websites. On these websites, we search for trials that are within our competence and contact the related Sponsors or CROs, providing relevant information about ourselves, who will respond if they are interested in our services. The Sponsor or CRO will consider entering into a contract for the study only after it has met with our personnel and has visited our facilities, and if the Sponsor or CRO is satisfied that we can conduct the trial and comply with the terms of its contract, which, as indicated above, are complex. Even then, the Sponsor or CRO may award the contract to a firm that it considers better qualified. · Sponsor or CRO websites. The process is similar to that described above for recruitment websites. · Personal contact.

We are currently conducting clinical trials for Sponsors and CROs in non-cirrhotic, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, a multivalent pneumococcal vaccine, iron deficiency anemia and the collection of biospecimen collections and samples across all ages and various therapeutic areas, and multiple medical conditions. We are actively seeking contracts, have bid on four and believe that we will be successful in obtaining some of them. We produced revenues of ~~approximately~~ $~~267~~301,~~220~~731 and $213,865 from our clinical trials business for the years ending May 31, ~~2024~~2025, and May 31, ~~2023~~2024, respectively.

Clinical Trial in Which We Will be the Sponsor

In the near future, Alpha Research intends to conduct clinical trials of hemp-derived cannabidiol (“CBD”) medical products, in which it will be the Sponsor. CBD derived from hemp containing less than 0.3% of tetrahydrocannabinol (“THC”) was legalized at the federal level by the Agriculture Improvement Act of 2018 and its sale and use of CBD products containing less than 0.3% of THC is legal in all states except for 18, which restrict sale and use for various reasons, including the age of the purchaser, non-medical use and the THC content; the Company will not sell its CBD product in any jurisdiction in which such sale is illegal, including these 18 states. The Company does not intend to conduct clinical trials of products that require approval of the FDA.

CBD is a naturally produced cannabinoid from the cannabis plant that differs from other cannabinoids, such as THC, for its structure and mechanism of action. CBD does not have psychoactive effects and does not alter the conscience and perception of the user. In contrast, CBD has been proven clinically to have anti-inflammatory, analgesic, anti-seizure, immunomodulatory and anxiolytic activity.

According to an article in Harvard Health Publishing, the consumer health education division of Harvard Medical School (“Cannabidiol (CBD): What we know and what we don’t,” published on September 24, 2021), there is strong evidence for the use of CBD in treating certain childhood epilepsy syndromes, and one CBD-based drug, Epidiolex, has been approved by the Federal Drug Administration for treating these conditions. This article states that animal studies, human research and self-reporting suggest that CBD may help with anxiety, insomnia, chronic pain and treatment of addiction. Other articles state, with varying degrees of certainty, that CBD may be used to treat other conditions, including mental disorders, such as depression, psychosis and PTSD; cancer-related symptoms, such as nausea, vomiting and pain; neurological conditions, such as Parkinson’s disease, Huntington’s disease, autism spectrum disorder and motor disorders; substance abuse; glioblastoma; high blood pressure; and sleep disorders. Initially, the Company intends to conduct research in the areas of endocannabinoid system physiology to study the normal endocannabinoid range in healthy individuals, the medical consequences of low endocannabinoid levels and the effects of cannabinoid administration in the organism. These studies will involve various methodologies, which will include blood tests, breathalyzer tests and electroencephalograms (EEGs) to determine the impact of cannabinoids on pathologies that have been linked to clinical endocannabinoid deficiencies such as irritable bowel syndrome, migraine and fibromyalgia. Research will also be conducted in oncology regarding the influence of cannabinoid-based treatments respecting cancer prevention, tumor size and viability, cancer-related symptoms and chemotherapy-induced symptoms. Finally, the Company intends to conduct research in anxiety disorders with a view to determining whether cannabinoids can reduce anxiety-related symptoms and improve quality of life.

The Company determined to conduct these clinical trials for the following reasons:

	·	According to Forbes Business Institute, the global CBD oil and CBD consumer health market is expected to grow from $39.54 billion in 2022 to $55.79 billion in 2028 at a compound annual growth rate of 47.49%.
	·	According to a Forbes Health Survey conducted by OnePoll, 60% of respondents reported that they have tried a cannabidiol (CBD) product and believe CBD has health and wellness benefits, including the potential to improve sleep, reduce anxiety and/or relieve pain.

Based on these factors and the expertise of the Company in conducting clinical trials, it believes that it can develop and test CBD products.

These trials will be conducted in the Company’s facilities, adding additional CRCs to handle the new studies. It will contract with an IRB to ensure all protocols are met and approved.

If a clinical trial indicates that a product is safe and effective, the Company intends to exploit it by selling or licensing it. Where possible, it will seek protection of intellectual property related to ~~and~~ the use of a product through patents and trademarking.

~~Sleep~~CBD ~~Center~~Products ~~Business~~and Research

In July 2022, the Company opened its Sleep Center, which served Houston-area patients who were interested in improving their sleep quality and enhancing their physical and mental well-being. The Sleep Center utilized state-of-the-art equipment. Its goal was to assess, diagnose, and treat sleep problems and provide patients with convenient and flexible care. During the year ended May 31, 2023, the Sleep Center treated only six patients and produced revenue of $900. The Company closed the Sleep Center in April 2023 because it was unable to obtain patients in the quantity needed to justify its operation and the Company believed that its manpower and financial resources would more effectively be used in its other activities.Background

CBD and Its Properties

CBD is a naturally produced cannabinoid from the cannabis plant that differs from other cannabinoids, such as THC, in its structure and mechanism of action. CBD does not have psychoactive effects and does not alter the consciousness and perception of the user.

CBD has been proven clinically to have anti-inflammatory, analgesic, anti-seizure, immunomodulatory and anxiolytic activity. For example, according to an article in Harvard Health Publishing, the consumer health education division of Harvard Medical School (“Cannabidiol (CBD): What we know and what we don’t,” published on September 24, 2021), there is strong evidence for the use of CBD in treating certain childhood epilepsy syndromes, and one CBD-based drug, Epidiolex, has been approved by the Federal Drug Administration for treating these conditions. This article states that animal studies, human research and self-reporting suggest that CBD may help with anxiety, insomnia, chronic pain and treatment of addiction. Other articles state, with varying degrees of certainty, that CBD may be used to treat other conditions, including mental disorders, such as depression, psychosis and PTSD; cancer-related symptoms, such as nausea, vomiting and pain; neurological conditions, such as Parkinson’s disease, Huntington’s disease, autism spectrum disorder and motor disorders; substance abuse; glioblastoma; high blood pressure; and sleep disorders.

Market

According to a report published in 2024 by Precedence Research, a market intelligence and consulting firm based in Canada and India, the global market size of CBD consumer health products was approximately $20.9 billion, of which U.S. markets accounted for about $9.0 billion in 2024. According to the report, this growth has been driven by the expansion in the availability of CBD products across various categories, such as dietary supplements, cosmetics, functional beverages, and wellness formulations, as well as by the growing consumer acceptance regarding the use of cannabidiol as an ingredient with therapeutic potential. The report projects that the U.S. market for CBD products will reach about $34.66 billion by 2034, representing a compound annual growth rate of approximately 14.45%, which reflects not only the strength of domestic demand but also the expected impact of innovation in new formulations and the possible easing of the regulatory framework. If these projections are fulfilled, CBD will become a significant sector in the U.S. health and wellness, impacting the pharmaceutical and mass consumer markets.

VitaCookies

The Company expects to launch its first CBD products in the State of Texas in the foods category of functional wellness edibles under the name “VitaCookies.” These cookies, which the Company believes have therapeutic properties, are formulated with cannabinoids and natural extracts to provide relief for a variety of medical conditions. Unlike other stigmatized formats, such as cigarettes or gummies, our team of physicians, chemists, and biologists has collaborated to develop a more refined, safe, and appealing product, designed to integrate seamlessly into patients’ daily lives through a reliable and enjoyable format.

The first launch includes:

	·	VitaDepression Cherry Cookies are intended to improve mood balance, sleep quality, and cognitive function by acting on the gut microbiota and reducing oxidative stress.

	·	VitaMenopause Mango Cookies are intended to relieve symptoms of perimenopause and menopause, such as hot flashes, fatigue, insomnia, and emotional changes.

	·	VitaFibromyalgia Strawberry Cookies are intended to reduce pain, neuroinflammation, and chronic fatigue in patients with fibromyalgia.

	·	VitaPainRelief Blackberry Cookies are intended to provide analgesic support for patients with chronic pain, reducing inflammation and improving daily well-being.

	·	VitaOsteoporosis Fig Cookies are designed for bone and joint health, with nutrients such as calcium, magnesium, and vitamin D that help prevent the loss of bone mineral density.

	·	VitaPrebiotic Plum Cookies are aimed at digestive health and the balance of the gut microbiota.

	·	VitaDiabetes Support Pecan Nut Cookies are intended to help regulate glucose and metabolism in individuals with Type 2 diabetes or insulin resistance.

	·	VitaCollagen Guava Cookies are intended to promote collagen production, thereby improving skin elasticity, joint function, and tissue recovery.

	·	VitaPTSD Dark Chocolate and Passion Fruit Cookies are intended to support patients with post-traumatic stress disorder, anxiety, and insomnia.

	·	VitaAnxiety Banana Cookies are formulated to assuage anxiety and emotional disturbances and to help balance the nervous system and regulate sleep.

The Company intends to launch VitaCookies in the near future. The Company will initially manufacture the VitaCookies on its own leased premises and market them initially through its own website. In the future, depending on the demand for VitaCookies, it may subcontract manufacturing.

For the time being, the Company plans to market only in the State of Texas, where its headquarters are located and VitaCookies will be manufactured. Because the FDA has taken the position that foods containing CBD cannot be introduced in interstate commerce, the Company will not sell VitaCookies and other products over which the FDA has jurisdiction outside the State of Texas, but may in the future expand its sales into other states if such sales become legal under federal law and the laws of the states where such sales are made. At that time, the Company will endeavor to sell these products to large national retail and pharmaceutical chains, specialized marketplaces for health and wellness products, such as wellness centers, vitamin stores, and to regional self-service chains, local supermarkets and liquor stores.

Development of New CBD Products

The Company intends to conduct research on the efficacy of CBD-based products. Possible areas of study are endocannabinoid system physiology to study the normal endocannabinoid range in healthy individuals; the medical consequences of low endocannabinoid levels; the effects of cannabinoid administration in the organism; the effect of cannabinoid-based treatments respecting cancer prevention, tumor size and viability, cancer-related symptoms and chemotherapy-induced symptoms; irritable bowel syndrome; migraine; anxiety; and fibromyalgia. These studies will involve various methodologies, which will include blood tests, breathalyzer tests and electroencephalograms (EEGs) to determine the impact of cannabinoids on pathologies that have been linked to clinical endocannabinoid deficiencies such as irritable bowel syndrome, migraine and fibromyalgia. Where appropriate, the Company will conduct clinical trials through Alpha Research Institute or an independent entity. If a product is found to be safe and effective, the Company intends to exploit it by selling or licensing it. Where possible, it will seek protection of intellectual property related to a product through patents and trademarking.

Patents and Trademarks

The Company has filed ten utility patent applications with the U.S. Patent and Trademark Office relating to cannabinoid-based compounds, formulations, and methods of treatment. These applications are intended to protect the Company’s innovations, compositions and methods of use. The applications are:

Application No. 18/905,128, filed on October 2, 2024, for a method of treatment for pancreatic cancer.

Application No. 18/918,386, filed on October 17, 2024, for a cannabinoid-based nanoplatform composition and methods for treating breast cancer by inhibiting VEGF.

Application No. 18/920,359, filed on October 18, 2024, for an integrative treatment for shingles based on cannabinoid compounds.

Application No. 18/922,127, filed on October 21, 2024, for a cannabinoid-based nanoplatform composition and methods for treating knee osteoarthritis.

Application No. 18/921,140, filed on October 21, 2024, for a cannabinoid-based nanoplatform composition and methods for treating menopause.

Application No. 18/924,087, filed on October 23, 2024, for a cannabinoid composition and method for treating symptoms of respiratory viral infections.

Application No. 18/929,972, filed on October 29, 2024, for an advanced cannabinoid therapeutic composition targeting the microbiota-gut-brain axis for comprehensive depression management.

Application No. 18/934,360, filed on November 1, 2024, for comprehensive cannabinoid compositions and methods for the management of anxiety disorders.

Application No. 18/942,512, filed on November 9, 2024, for an advanced cannabinoid formulation for targeted management of multiple sclerosis.

Application No. 18/957,035, filed on November 22, 2024, for cannabinoid formulations and methods for oral care and health management.

No assurance can be given that any of these applications will result in the issuance of patents.

Employees

The Company has two employees, namely its executive officers, who serve full-time. It meets its other manpower needs through approximately 14 independent contractors; the number of these personnel changes from time to time in accordance with the Company’s staffing needs. For a description of the services provided by these independent contractors, see the descriptions of the three segments of the Company’s business.

Concentration of Revenues

The Company has depended on a few customers of Alpha Research Business for substantial portions of its revenue. For the year ended May 31, ~~2024~~2025, the Company had revenues of $~~248~~303,~~841~~022, of which 6266.87%, and 24.1% ~~and 4.0%~~ were received from ~~three~~two customers. For the year ended May 31, ~~2023~~2024, the Company had revenues of $~~316~~248,~~825~~841, of which 63 62.98%, ~~27.2%~~ and 524.1% were received from ~~three~~two customers.

Description of Property

The Company leases approximately 1,367 square feet at 6201 Bonhomme Road, Suite 435N, Houston, Texas, under a lease dated April 12, 2024, and amended on June 18, 2025. The lease, ~~which~~as amended, ~~has~~added a one-year term that commenced on ~~May~~June 1, ~~2024.~~2025, ~~provides~~at ~~for~~ a base rent of $1,~~631~~730 per month. ~~These premises are shared by PUI and Alpha Research Institute.~~

~~Two~~The ~~of the~~ Company’s ~~officers~~is ~~leased~~using ~~1,400 square~~as ~~feet~~office inspace ~~Houston, Texas, at 1625 Main St., Houston, Texas, under~~ a ~~lease the term~~ portion of ~~which~~an ~~commenced~~apartment onleased ~~March~~by ~~15,~~one ~~2023, and expired on September 14, 2023, at a rent~~ of ~~$3,168~~its ~~per month; these~~ officers ~~have~~with ~~made~~an aarea ~~portion~~ of ~~these premises available to the Company for use as office space~~1,400 ~~for~~square ~~which~~feet ~~the~~in ~~Company pays them $2~~Houston,~~817~~ ~~per month. These officers entered into a new lease for these premises~~Texas, ~~which commenced~~at on1625 ~~September~~Main 15St, ~~2023~~Houston, ~~and will expire on September 14~~Texas, ~~2024, at a rent of $3,164 per month, and they made a portion of these~~for ~~premises~~which ~~available~~it tois ~~the~~reimbursing ~~Company~~him ~~for~~at ~~use as office space, for which~~ the ~~Company~~rate ~~is paying them~~ $2,817 per month. One of these officers died in January 2024. For further information, see “Certain Relationships and Related Party Transactions—Lease.” The surviving officer intends to renew this lease and make a portion of these premises available to the Company for use as office space on the same terms,

Legal Proceedings

The Company is not a party to any litigation and is not aware of any threatened litigation.

Off-Balance Sheet Arrangements

We have no off-balance-sheet arrangements.

Government Regulation

The Company’s businesses are affected by laws and regulations relating to cannabis and clinical trials. In the future, the Company may sell cannabinoid products that are subject to legal restriction and regulation in some states and, although not subject to federal regulation today, could be regulated or restricted in the future. The Company intends to comply with all such restrictions and regulations.

The Company and its expenditures, earnings and competitive position have not been materially affected by compliance with the above or other governmental regulations, including those relating to climate change. See also Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations – Climate Change.

The Company believes that it is in compliance with all material government regulations.

Information About Our Executive Officers

The names and ages of the Company’s executive officers and their positions with the Company are as follows:

Name (Age)	Present Position (Effective Date)	Positions Held During Past Five Years (Effective Date)
Dante Picazo (68)	Chief Executive Officer, Chief Financial Officer and Director (2019)	Chief Executive Officer, Chief Financial Officer and Director (2019)
Dante Picazo (69)	Chief Executive Officer, Chief Financial Officer and Director (2019)	Chief Executive Officer, Chief Financial Officer and Director (2019)
John Jones (59)	Treasurer and Director (2024)	Treasurer and Director (2024)
John Jones (60)	Treasurer and Director (2024)	Treasurer and Director (2024)

There are no family relationships between any of the officers named above and, except for an Agreement, dated as of August 19, 2024, by and among the Company, John Jones and Barbara Kamienski (the “Jones Agreement”), there is no arrangement or understanding between any of the officers named above and any other person pursuant to which he was selected as an officer. For information regarding the Jones Agreement, see “Certain Relationships and Related Transactions, and Director Independence – Jones Agreement”). The board of directors (the “Board”) appointed each of the officers named above to hold office until his successor is elected and qualified or until his earlier resignation or removal.

Further information about the Company’s officers and directors appears in Part III of this report.

Item 1A.

Risk Factors.

The Company is a smaller reporting company as defined by Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”) and is not required to provide information under this item.

Item 1B.

Unresolved Staff Comments.

None.

Item 1C.

Cybersecurity.

The Company does not believe that it is subject to material cybersecurity risks and does not expect to incur material costs in connection with cybersecurity. The Company does not believe that it has been the object of any cyberattack.

Item 2.

Properties.

The Company leases ~~premises~~approximately of 1,367 square feet ~~located~~ at 6201 Bonhomme Road, ~~Suites~~Suite 435N, Houston, Texas, under a lease dated April 12, 2024, and amended on June 18, 2025. The lease, ~~provides~~as ~~for~~amended, added a one-year term that commenced on June 1, 2025, at a base rent of $1,~~631~~730 per month. For information ~~regarding~~ regarding the recording of the right-of-use asset and the lease liability in the consolidated balance sheets ~~in respect of a prior lease~~, see Note 5 to the Company’s financial statements.

Two of the Company’s officers leased 1,400 square feet in Houston, Texas (the “Officers’ Leased Property”), under a lease, the term of which commenced on February 29, 2020, and expired on March 14, 2022, at a rent of $3,449 per month. These officers made a portion of these premises available to the Company for office space on a month-to-month basis, for which the Company paid them $2,817 per month. On March 15, 2022, these officers entered into a new lease for the same premises, which expired on September 14, 2022, at a rent of $3,008 per month, and these officers continued to make a portion of these premises available to the Company for use as office space, for which the Company is paying them $2,817 per month on a month-to-month basis. On September 15, 2022, the officers that leased the Officers’ Leased Property entered into a new lease for these premises, which expired on March 14, 2023, at a rent of $3,038 per month, and these officers continued to make a portion of these premises available to the Company for use as office space, for which the Company paid them $2,817 per month. On March 2, 2023, these officers entered into a new lease for the same premises, which expires on September 14, 2023, at a rent of $3,168 per month and they continued to make a portion of these premises available to the Company for use as office space, for which the Company paid them $2,817 per month. On September 6, 2023, these officers entered into a new lease of this property, which commenced on September 15, 2023, and will expire on September 14, 2024, at a rent of $3,164 per month and they are made a portion of these premises available to the Company for use as office space, for which the Company is paying them $2,817 per month.

Item 3.

Legal Proceedings.

None.

Item 4.

Mine Safety Disclosures.

Not applicable.

1215

PART II

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities.

The Common Stock is quoted on the OTC Pink tier of the alternate trading system operated by OTC under the trading symbol CBIH~~; prior to August 17, 2023, the trading symbol was CHNC~~. Market quotations for shares of Common Stock shown on OTC’s quotation system reflect inter-dealer prices without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.

On September 10, ~~2024~~2025, the closing price for the Common Stock quoted by OTC was $0.~~0008~~0005 per share.

As of the date of this Report, there were ~~419~~420 record holders of the shares of the Common Stock, of which approximately 21.48 billion shares were freely tradable.

~~The~~As of the date of this report, the exemption from registration afforded by Rule 144 is available for all other outstanding shares of Common Stock that have been held for 6 months after they were paid for in full.

Item 6.

Reserved.

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The financial information discussed below is derived from the Company’s audited consolidated financial statements at May 31, ~~2024~~2025, which were prepared and presented in accordance with generally accepted accounting principles (“GAAP”). This financial information is only a summary and should be read in conjunction with the audited financial statements and related notes contained herein, which more fully present the Company’s financial condition and results of operations at that date. The results set forth in these consolidated financial statements are not necessarily indicative of the Company’s future performance. This item and other parts of this report contain forward-looking statements that involve risks and uncertainties. Actual results may differ significantly from the results discussed in forward-looking statements.

Information about the Company

The Company, headquartered in Houston, Texas, conducts clinical trials for Sponsors and CROs and as a Sponsor through Alpha Research Institute, ~~and~~ cannabis-related education in classrooms, seminars and online through Pharmacology University and sales of CBD products. For detailed information about the Company and its operations, see “Business.”

The Company’s fiscal year begins on June 1 in each year and ends on May 31 in the following year.

Going Concern

As indicated in Note 3 of the notes to the audited consolidated financial statements for the year ended May 31, ~~2024~~2025, and the report thereon of the Company’s independent auditing firm, there is substantial doubt as to the ability of the Company to continue as a going concern. The Company has incurred recurring losses and recurring negative cash flow from operating activities and has an accumulated deficit, and its ability to continue as a going concern depends on the successful execution of its operating plan, which includes increasing sales of existing services and introducing new services, as well as raising either debt or equity financing.

The Company needs substantial additional capital to fund its business, ~~including the completion of its business plan~~ and ~~repayment~~repay of its debts. No assurance can be given that any additional capital can be obtained or, if obtained, will be adequate to meet its needs, and the Company may need to take measures to remain a going concern. If adequate capital cannot be obtained on a timely basis and satisfactory terms, the Company’s operations could be materially negatively impacted, or it could be forced to terminate its operations.

1316

Impact of the COVID-19 Pandemic

The COVID-19 pandemic adversely impacted the Company and its financial results in different ways, depending on the particular business operation, as follows:

Pharmacology University Business. The Company encountered quarantines, restrictions on gatherings and other governmental regulations that precluded classroom education, as well as restrictions on travel that reduced consulting activities. The Company reduced the impact of the pandemic by developing online educational programs and transitioning its workforce to a remote working environment without reducing its workforce. Revenue from this operation was increased from $18,323 in the year ended May 31, 2019 (unaudited), to $44,799 and $38,440 in the years ended May 31, 2020, and May 31, 2021, respectively; revenue for the year ended May 31, 2022, was $18,341, for May 31, 2023, was $42,655 and for the year ended May 31, 2024, was $36,335.

Clinical Trials. Quarantines, restrictions on gatherings and other governmental regulations, amplified by potential patients’ fears of contracting COVID-19 at the Company’s clinics, negatively affected clinical trials. In addition, these clinics were subject to closure if cases of the virus were detected. Revenue from this operation changed from $165,666 in the year ended May 31, 2019 (unaudited), to $84,979 and $706,008 in the years ended May 31, 2020, and May 31, 2021, respectively; revenue for the year ended May 31, 2022, was $196,637, for the year ended May 31, 2023, was $266,280 and for the year ended May 31, 2024, was $213,865.

The Company believes that, although the COVID-19 pandemic adversely affected the Company’s operations and, especially with respect to its Pharmacology University business, and caused the Company to change the way in which it operates today, it is no longer affected by the pandemic.

Change of Corporate Name

The Company believes that it may have been negatively impacted by the association of the pandemic with the People’s Republic of China because “China” appeared in its former corporate name. Although the Company has no operations in or any relationship with China, the Company believes that potential investors may have been deterred from considering the Company because of concerns related to that country. For this reason, and because the Company’s corporate name did not reflect its activities, it changed its name to Cannabis Bioscience International Holdings, Inc. on December 6, 2022.

Overview

The Company provides educational systems focused on medical cannabis in the United States and Latin America, as well as worldwide through online education, ~~and~~ services in therapeutic ~~areas~~ areas of clinical trials and CBD products. The Company’s operating units and their activities were:

· Alpha Research Institute – Clinical trials and medical research. · Pharmacology University: – Education, consulting, digital publishing, marketing, and franchising related to medical cannabis. · CBD Business – Sales of CBD products.

The Company operated a Sleep Center, which diagnosed sleep-related disorders. Its operations were terminated on April 30, 2023.

For further information concerning the Company and its business, see “Business.”

Results of Operations

Comparison of the Year Ended May 31, ~~2024~~2025, and the Year Ended May 31, ~~2023~~2024

The following table sets forth information from the consolidated statements of operations for the years ended May 31, ~~2024~~2025, and May 31, ~~2023~~2024.

	Year Ended May 31,
	2024			2023
	2025			2024
Revenues	$	~~248~~303,~~841~~022		$	~~316~~248,~~825~~841
Cost of revenues		4540,~~599~~106			9345,~~450~~599
Gross profit		~~203~~262,~~242~~916			~~223~~203,~~375~~242
Total operating expenses		~~689~~684,~~382~~281			1689,~~206,746~~382
Operating loss		(~~486~~421,~~140~~365	)		(~~983~~486,~~371~~140	)
Non-operating income (expense):
Note discount expense		(11,000	)		–
Amortization of discount		(44,154	)		–
Forgiveness of debt		–			41,765
Note discount		–			(11,000	)
Interest		(154,206	)		(90,973	)
Forgiveness of debt		23,638			–
Net loss	$	(651,345	)	$	(1,032,579	)
Change in fair value of derivative liabilities		29,323			–
Interest		(136,262	)		(154,206	)
Net loss	$	(548,820	)	$	(651,345	)

Revenues

Revenues were $~~248~~303,~~841~~022 and $~~316~~248,~~825~~841 for the years ended May 31, ~~2024~~2025, and May 31, ~~2023~~2024, respectively, primarily due to aan ~~decrease~~increase of $5287,~~415~~866 in revenues from clinical trial contracts, which were $~~266~~213,~~280~~865 in the earlier period and $~~213~~301,~~865~~731 in the later. Revenues from cannabis-related educational classes and seminars were $61,~~335~~291 for the year ended May 31, ~~2024~~2025, as compared with $426,~~655~~335 for the year ended May 31, ~~2023~~2024, because the Company conducted fewer ~~classes~~ classes and seminars in the year ended May 31, 2024. Consulting fees were $~~28,641~~0 for the year ended May 31, ~~2024~~2025, versus $828,~~333~~ 641 for the year ended May 31, ~~2023~~2024.

Operating Expenses

Operating expenses for the years ended May 31, ~~2024~~2025, and May 31, ~~2023~~2024, consisted of the following:

	Years Ended May 31,
	2024		2023
	2025		2024
General and administrative	$	~~123~~101,~~759~~906	$	~~177~~123,~~110~~759
Contract labor		~~205~~175,~~984~~420		~~659~~205,~~651~~984
Professional fees		~~232~~317,~~844~~137		~~245~~232,~~691~~844
Officer compensation		3824,000		4538,~~735~~000
Rent		8665,~~730~~301		7186,~~942~~730
Travel		~~2,065~~517		62,~~617~~065
Total operating expenses	$	~~639~~684,~~382~~281	$	1689,~~206,746~~382

~~The~~Officer ~~decrease~~compensation indecreased ~~contract~~because ~~labor~~an ~~was due to a substantial~~officer ~~reduction in staff to write, translate, and produce audiobooks, e-books, and online videos~~died. ~~Professional~~Rent ~~fees~~was ~~decreased~~reduced by $721,~~735~~429 because ~~the~~ ~~Company’s~~a ~~legal~~lease terminated and ~~accounting costs decreased after~~ the Company’s ~~registration~~entered ~~statement~~into ~~became~~a ~~effective~~new onlease ~~December 6,~~for ~~2023.~~a ~~Officer~~smaller ~~compensation~~area ~~decreased because an officer left the Company~~ and ~~was not replaced. Rent increased by $14,788 because~~ rent ~~for the Company’s premises increased when the lease was renewed~~.

Operating Loss

For the reasons set forth above, operating loss ~~decreased~~ decreased from $~~983~~486,~~371~~140 in the year ended May 31, ~~2023~~2024, to $~~486~~421,~~140~~365 in the year ended May 31, ~~2024~~2025.

Interest

Interest was $90136,~~973~~262 in the year ended May 31, ~~2023~~2025, and $154,206 in the year ended May 31, 2024.

Other Income

InOn May 13, 2024, the ~~year~~Company ~~ended~~agreed ~~May~~to 31settle $38,638 ~~2023~~owing under a financing agreement in consideration of a payment of $15,000, which the Company ~~recorded other~~made ~~income~~on ofJune 12, 2024. Under ASC 470-50-40, the $4123,~~675~~638 ~~from~~difference between the ~~forgiveness~~fair value of ~~PPP~~the ~~loans~~extinguished debt and the fair value of the payment has been treated as gain.

Net Loss

Net loss for the year ended May 31, 2024, was $~~631~~651,345, compared with a net loss of $1548,~~032,579~~820 for the year ended May 31, ~~2023~~2025, for the reasons set forth above ~~in relation to loss from operations and the effect of other income received in these years~~.

Liquidity and Capital Resources

At May 31, ~~2024~~2025, the Company had $~~755~~12,952 in cash and cash equivalents, accounts receivable of $206,~~139~~380, negative working capital of $~~860~~916,~~416~~878 and no commitments for capital expenditures. At May 31, ~~2023~~2024, the Company had $~~8,913~~755 in cash and cash equivalents, accounts receivable of $1020,~~549~~139, negative working capital of $~~366~~860,~~085~~417 and no commitments for capital expenditures. The Company had cash in the amount of $~~1,028~~228 on September 10, ~~2024~~2025.

During the years ended May 31, ~~2024~~2025, and May 31, ~~2023~~2024, the Company had net cash used in operations of $~~479~~329,~~382~~627 and $~~898~~479,~~367~~382, respectively, and net cash provided by financing activities of $~~471~~341,~~224~~ 824 and $~~875~~471,~~298~~224, respectively. The Company had accumulated deficits of $5,~~334~~882,~~081~~901 at May 31, ~~2024~~2025, and $45,~~682~~334,~~736~~081 at May 31, ~~2023~~ 2024.

~~Delays~~Since inJune ~~payments by Sponsors and CROs that have affected~~1, ~~and if they were to recur~~2023, ~~could affect,~~ the Company’s ~~cash~~has ~~flows.~~raised capital as follows:

Since June 1, 2022, the Company has raised capital as follows:

	·	In the years ended May 31, 2025, and the year ended May 31, 2024, the Company received $244,250 and $70,000, respectively, from sales of Common Stock to private investors.

	·	In the years ended May 31, 2025, and May 31, 2024, the Company received loans of $120,907 (of which $105,187 was related-party loans) and $428,201 (of which $398,041 was related-party loans), respectively.

	·	In the years ended May 31, 2024, and the year ended May 31, 2023, the Company received $70,000 and $801,956, respectively, from sales of Common Stock to private investors.
	·	In the years ended May 31, 2024, and May 31, 2023, the Company received loans of $428,201 (of which $398,041 was a related-party loan) and $73,332, respectively.

16In the year ended May 31, 2024, the Company has offered 6,250,000,000 shares of Common Stock to the public at an offering price of $0.0008 per share. If this offering had been fully sold, the Company would have raised new capital of $5,000,000. However, no shares were sold. The Company does not intend to conduct a public offering of Common Stock until the market price for its Common Stock increases substantially. Thus, the Company believes that it will be able to raise equity capital only through the sale of shares of Common Stock in private transactions at discounts from the market price for Common Stock, which may be substantial.

The Company has offered 6,250,000,000 shares of Common Stock to the public at an offering price of $0.0008 per share (the “Offering”). If the Offering had been fully sold, the Company would have raised new capital of $5,000,000. However, as of the date of this Report, no shares have been sold and the Company believes that it will not be able to sell any of these shares until the market price for its Common Stock exceeds the public offering price of the Offering for a substantial period. As a result, the Company believes that it will be able to raise equity capital only through the sale of shares of Common Stock in private transactions at discounts from the market price for Common Stock, which may be substantial. The Company believes that, for the time being, it will not be able to attain the goals described under “Business Plan” in the prospectus for the public offering and that it will need to obtain funding ~~for~~of ~~the~~ $2,~~425~~000,000 ~~required~~for ~~to attain these goals and~~ its ~~estimated~~ ~~that other~~ capital ~~needs~~requirements ofto ~~$2,000.000~~fully ~~(including~~fund ~~operating~~its ~~costs~~business offor ~~$600,000,~~the ~~legal/accounting~~next ~~costs~~two ofyears ~~$400,000, overhead of $800,000~~ and provide a reserve for contingencies of $~~200~~500,000 ~~for the next two years)~~ through revenue from operations, profits, private sales of its equity securities, ~~loans~~ or ~~a public offering at a lower offering price that for the Offering~~loans.

There is no assurance that such funding will be available on acceptable terms or at all or that the Company will attain profitability. If the Company cannot raise sufficient funds when required or on acceptable terms, it may have to reduce its operations significantly or discontinue them entirely. To the extent that funds are raised by issuing equity securities or securities that are convertible into the Company’s equity securities, its stockholders may experience significant dilution. If the Company is successful in raising funds for its ~~business~~businessand ~~plan and~~ in carrying it out, it expects to become profitable in the year ending May 31, ~~2025~~2026, and beyond.

The Company believes, but cannot assure, that sales of VitaCookies and fees for classes and seminars relating to Law HB 46 may result in substantial revenue and profits.

Financial Outlook

The Company has not generated significant revenues and has never been profitable. However, it believes that its growing portfolio of CBD products and intellectual property indicate that the Company is on the right track. The Company believes that the imminent introduction of VitaCookies will generate additional revenue and enable it to become profitable in the current fiscal year, provided that it is able to keep its expenses near current levels. The Company pays some of its officers and directors in shares of Common Stock and expects to continue doing so for the foreseeable future. While paying these officers and directors in shares conserves cash, which is important in light of the Company’s limited capital, GAAP requires that the value of these shares be presented as an operating expense, thereby reducing operating income. The Company hopes that in the future, it will increase revenue and profits by the introduction of state-of-the-art nanotechnology products, including nanoemulsion-based delivery systems, which improve solubility, stability, targeted delivery and the overall bioavailability of therapeutic compounds.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Smaller Growth Company

We are a smaller reporting company as defined in Item 10(f)(1) of Regulation S-K. As such, we may take advantage of certain of the scaled disclosures available to smaller reporting companies as long as (i) the market value of our voting and non-voting common stock held by non-affiliates is less than $250 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our voting and non-voting common stock held by non-affiliates is less than $700 million measured on the last business day of our second fiscal quarter. As a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and have reduced disclosure obligations regarding executive compensation; and, as long as we remain a smaller reporting company with less than $100 million in annual revenue, we will not be required to obtain an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.

Climate Change

The Company’s business, financial condition, and results of operations have not been materially impacted by federal and state legislation and regulation and international accords regarding climate change, but it cannot predict how they may be impacted in the future. The Company has had no material past capital expenditures for climate-related projects and, unless there are regulatory changes, does not expect to incur them in the future.

Long-Term Obligations

The Company has no long-term obligation that it expects to have a material impact on its liquidity or capital resources.

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk.

The Company is a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and is not required to provide information under this item.

1720

Items 8.

Financial Statements and Supplementary Data.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Report of Independent Registered Public Accounting Firm for Year Ended May 31, 2024 (PCAOB #6771)	F-1
Report of Independent Registered Public Accounting Firm for Year Ended May 31, 2025 (PCAOB #6771)	F-1
Consolidated Balance Sheets	F-2
Consolidated Statements of Operations	F-3
Consolidated Statements of Cash Flows	F-4
Consolidated Statements of Stockholders’ Deficiency	F-5
Notes to Consolidated Financial Statements	F-6

1821

VICTOR MOKUOLU, CPA PLLC

Accounting | Advisory | Assurance & Audit | Tax

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders

Cannabis Bioscience International Holdings, Inc. (formerly ~~named~~ China Infrastructure Construction Corp.)

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Cannabis Bioscience International Holdings, Inc. (formerly; China Infrastructure Construction Corp) (the “Company”) as of May 31, ~~2024~~2025, and ~~2023~~May 31, 2024, and the related consolidated statements of operations, stockholders’ ~~deficit~~deficiency, and cash flows for each of the ~~year~~ two years in the period ended May 31, ~~2024 and 2023~~2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of May 31, ~~2024~~2025, and ~~2023~~May 31, 2024, and the results of its operations and its cash flows for each of the two years in the period ended May 31, ~~2024~~2025, in conformity with accounting principles generally accepted in the United States of America.

Substantial ~~doubt~~Doubt about the Company'’s ~~ability~~ ability to continue as a Going Concern

The accompanying financial statements have been prepared assuming ~~that~~ the Company will continue as a going concern. As discussed in Note 3, Going Concern, to the consolidated financial statements, the Company has suffered recurring losses ~~since~~from ~~inception,~~operations ~~has~~and had a ~~stockholders’~~working capital deficit of $916,878 and ~~the~~an ~~Company~~accumulated ~~has~~deficit ~~not generated sufficient revenues to~~of ~~date~~$5,882,901 toas ~~cover~~on ~~its~~May ~~operating~~31, ~~costs~~2025. –These ~~these~~ factors raise substantial doubt about ~~its~~the Company’s ability to continue as a going concern. Management'’s plans in regard to these matters are also described in Note 3, Going Concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

~~Critical~~A critical audit ~~matters~~matter ~~are~~is ~~matters~~a matter arising from the current period audit of the financial statements that ~~were~~was communicated or required to be communicated to the ~~audit~~Company’s ~~committee and~~governance and that: (1) ~~relate~~relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

/s/ Victor Mokuolu, CPA PLLC

We have served as the Company’s auditor since 2023.

Houston, Texas

September 1322, ~~2024~~2025

PCAOB ID: 6771

www.vmcpafirm.com | Ph: 713.588.6622 | Fax: 1.833.694.1494 | ask@vmcpafirm.com

F-1

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.

(formerly named China Infrastructure Construction Corp.)

CONSOLIDATED BALANCE SHEETS

	May 31,
	2024			2023
	2025			2024
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	~~755~~12,952		$	~~8,913~~755
Accounts receivable		206,~~139~~380			920,~~951~~139
Related party receivables		9,155			–
Other current assets		598			598
TOTAL CURRENT ASSETS		2129,~~492~~085			1921,~~462~~492
Right-of-use asset		352,~~670~~795			2335,~~920~~670
TOTAL ASSETS	$	5731,~~162~~880		$	4357,~~382~~162
LIABILITIES AND STOCKHOLDERS’ DEFICIENCY
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
CURRENT LIABILITIES
Accounts payable and accrued expenses	$	~~196~~100,~~088~~343		$	~~111~~165,~~299~~858
Bank overdraft		~~2,408~~–			–2,408
Deferred revenue		–			28,641
Credit cards		30,327			30,230
Related-party payables		503,214			105,173
Accrued interest		22,095			–
Short-term loans		151,267			121,407
Related party payables		623,474			518,287
SBA loan – current		7,054			14,592
Short-term loans (net of amortization of loan fees)		111,722			136,194
Lease liabilities – current		21,877			4,435
SBA loans		14,592			7,054
TOTAL CURRENT LIABILITIES		881,908			385,547
Derivative liabilities		29,322			–
Lease liabilities		4,906			21,877
Convertible note		9,182			–
TOTAL CURRENT LIABILITIES		945,963			881,909
LONG-TERM LIABILITIES
SBA loan – noncurrent		249,361			249,500
Notes payable		–			–
Lease liabilities – noncurrent		4,906			–
SBA loan		249,500			249,361
TOTAL LONG-TERM LIABILITIES		254,267			249,500
Lease liabilities		–			4,906
TOTAL LIABILITIES		1,136,175			635,047
TOTAL LONG-TERM LIABILITIES		249,500			254,267
STOCKHOLDERS’ DEFICIENCY
TOTAL LIABILITIES		1,195,463			1,136,175
Authorized 10,000,000 shares of preferred stock, of which 2,500,000 shares have been designated Series A Convertible Preferred Stock and 1,000 shares have been designated Series B Preferred Stock		–			–
STOCKHOLDERS' DEFICIENCY
Common stock, without par value: 20,000,000,000 shares authorized 10,431,749,347 and 10,059,677,919 shares issued and outstanding at May 31, 2024, and May 31, 2023, respectively.		–			–
Preferred stock: 10,000,000 shares, without par value, authorized, of which 2,500,000 shares have been designated Series A Convertible Preferred Stock and 2,000 shares have been designated Series B Preferred Stock (2,000 and 1,000 shares outstanding at May 31, 2025, and May 31, 2024, respectively)		–			–
Additional paid-in capital		4,255,068			4,091,071
Common Stock, without par value: 20,000,000,000 shares authorized 11,626,749,347 and 10,431,749,347 shares issued and outstanding at May 31, 2025, and May 31, 2024, respectively		–			–
Accumulated deficit		(5,334,081	)		(4,682,736	)
Additional paid-in capital		4,719,318			4,255,068
TOTAL STOCKHOLDERS’ DEFICIENCY		(1,079,013	)		(591,665	)
Accumulated deficit		(5,882,901	)		(5,334,081	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY	$	57,162		$	43,382
TOTAL STOCKHOLDERS' DEFICIENCY		(1,163,583	)		(1,079,013	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	$	31,880		$	57,162

The accompanying notes are an integral part of these consolidated financial statements.

F-2

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.

(formerly named China Infrastructure Construction Corp.)

CONSOLIDATED STATEMENTS OF OPERATIONS

	May 31,
	2024			2023
	2025			2024
Revenues	$	~~248~~303,~~841~~022		$	~~316~~248,~~825~~841
Cost of revenues		4540,~~599~~106			9345,~~450~~599
Gross profit		~~203~~262,~~242~~916			~~223~~203,~~375~~242
Cost and expenses
General and administrative		~~123~~101,~~759~~906			~~177~~123,~~110~~759
Contract labor		~~205~~175,~~984~~420			~~659~~205,~~651~~984
Professional fees		~~232~~317,~~844~~137			~~245~~232,~~691~~844
Officer compensation		3824,000			4538,~~735~~000
Rent and lease		8665,~~730~~301			7186,~~942~~730
Travel expenses		2,065			6,617
Travel		517			2,065
Total operating expenses		~~689~~684,~~382~~281			1689,~~206,746~~382
Operating loss		(~~486~~421,~~140~~365	)		(~~983~~486,~~371~~140	)
Other income (expense)
Other income (Expense)
Loan discount		(11,000	)		–
Amortization of discount		(44,154	)		–
Forgiveness of debt		–			41,765
Note discount		–			(11,000	)
Interest		(154,206	)		(90,973	)
Forgiveness of debt		23,638			–
Total other income		(165,206	)		(49,208	)
Change in fair value of derivative liabilities		29,323			–
Net loss	$	(651,345	)	$	(1,032,579	)
Interest		(136,262	)		(154,206	)
Average common stock outstanding		10,317,612,225			9,001,539,324
Total other income		(127,455	)		(165,206	)
Average earnings (loss) per share	$	(0.00006	)	$	(0.00011	)
Net loss	$	(548,820	)	$	(651,345	)
Average common stock outstanding		10,716,352,087			10,317,612,225
Average earnings (loss) per share	$	(0.00005	)	$	(0.00006	)

The accompanying notes are an integral part of these consolidated financial statements.

F-3

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.

(formerly named China Infrastructure Construction Corp.)

CONSOLIDATED STATEMENTS OF CASH FLOWS

	May 31,
	2024			2023
	2025			2024
OPERATING ACTIVITIES
Net loss	$	(~~651~~548,~~345~~820	)	$	(1651,~~032,579~~345	)
Adjustment for issuance of common stock (non-cash expense)		112,997			–
Adjustment to reconcile net loss:
Amortization of right-of-use asset and liability		(11,750	)		36,378
Issuance of common stock for services		220,000			112,997
Share-based compensation		–			12,000
Amortization of right-of-use asset and liability		32,875			(11,750	)
Forgiveness of PPP loan		–			(41,666	)
Loss on valuation of convertible notes		29,322			–
Adjustment to reconcile net loss
Changes to lease liabilities		22,348			(43,423	)
Changes in assets and liabilities
Accounts receivable		(10,188	)		(4,935	)
Accounts receivables		13,759			(10,188	)
Accounts payable and accrued expenses		84,789			43,089
Bank overdraft		(2,408	)		2,408
Bank overdraft		2,408			–
Related party receivables		(9,155	)		–
Deferred revenue		(28,641	)		28,641
Accounts payable and accrued expenses		(65,515	)		84,789
Accrued interest on SBA loan		–			21,571
Credit cards		97			–
Interest on SBA loan		–			(6,778	)
Accrued interest		22,095			–
Advances by related party		–			99,015
Deferred revenue		–			(28,641	)
Repayments of related party advances		–			(9,680	)
Lease liability		(21,877	)		22,348
NET CASH USED IN OPERATIONS		(~~479~~329,~~382~~627	)		(~~898~~479,~~367~~382	)
FINANCING ACTIVITIES
Proceeds from issuance of common stock		70244,~~000~~250			~~801~~70,~~966~~000
Proceeds from short-term loans		29,860			73,332
Proceeds from (repayments of) short-term loans		(24,472	)		29,860
Repayment of SBA loan – current		(7,538	)		–
Proceeds from shareholders’ loans		7,538			(7,538	)
Payments on SBA loan		(139	)		–
Changes in notes payable		9,182			–
Repayment of related-party loan		(19,000	)		–
Payments to SBA Loan		139			(139	)
Proceeds from related-party loan		398,041			–
Repayment of related party loan		–			(19,000	)
NET CASH PROVIDED BY FINANCING ACTIVITIES		471,224			875,298
Proceeds from related party loan		105,187			398,041
NET DECREASE IN CASH		(8,158	)		(23,069	)
NET CASH PROVIDED BY FINANCING ACTIVITIES		341,824			471,224
CASH AT BEGINNING OF PERIOD		8,913			31,982
NET INCREASE (DECREASE) IN CASH		12,197			(8,158	)
CASH AT END OF PERIOD	$	755		$	8,913
CASH AT BEGINNING OF PERIOD		755			8,913
CASH AT END OF PERIOD	$	12,952		$	755
Supplemental disclosure of cash flow information
Cash paid for interest	$	~~154~~136,~~206~~262		$	93,472

The accompanying notes are an integral part of these consolidated financial statements.

F-4

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.

(formerly named China Infrastructure Construction Corp.)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY

	Series A Convertible Preferred Stock					Series B Preferred Convertible Stock				Common Stock					Additional Paid-In			Accumulated
	Shares		Amount			Shares		Amount		Shares			Amount		Capital			Deficit			Total
Balance - May 31, 2022		2,500,000	$	2,500			–	$	–		8,612,998,299		$	–	$	3,286,605		$	(3,650,157	)	$	(361,052	)
Sales of common stock for cash		–		–			–		–		2,042,146,825			–		801,966			–			801,966
Change in par value of common stock		–		(2,500	)		–		–		–			–		2,500			–			–
Exchange of Series B Preferred Stock for common stock		–		–			1,000		–		(595,467,205	)		–		–			–			–
Net loss		–		–			–		–		–			–		–			(1,032,579	)		(1,032,579	)
Balance - May 31, 2023		2,500,000	$	–			1,000	$	–		10,059,677,919		$	–	$	4,091,071		$	(4,682,736	)	$	(591,665	)
Balance - May 31, 2023		2,500,000	$	–			1,000	$	–		10,059,677,919		$	–	$	4,091,071		$	(4,682,736	)	$	(591,665	)
Sales of common stock for cash		–		–			–		–		272,071,428			–		70,000			–			70,000
Issuance of common stock for service		–		–			–		–		100,000,000			–		75,000			–			75,000
Issuance of common stock for employees		–		–			–		–		–			–		37,997			–			37,997
Rescission of common stock sale		–		–			–		–		–			–		(19,000	)		–			(19,000	)
Shares withdrawal		–		–			–		–		–			–		(19,000	)		–			(19,000	)
Net loss		–		–			–		–		–			–		–			(651,345	)		(651,345	)
							–		–
Balance - May 31, 2024		2,500,000	$	–			1,000	$	–		10,431,749,347		$	–	$	4,255,068		$	(5,334,081	)	$	(1,079,013	)
Balance - May 31, 2024		2,500,000	$	–			1,000	$	–		10,431,749,347		$	–	$	4,255,068		$	(5,334,081	)	$	(1,079,013	)
Issuance of Series B Preferred		–		–			1,000		–		–			–		–			–			–
Sales of common stock for cash		–		–			–		–		575,000,000			–		158,000			–			158,000
Issuance of common stock for service		–		–			–		–		325,000,000			–		250,000			–			250,000
Issuance of common stock for repayment of note payable		–		–			–		–		345,000,000			–		86,250			–			86,250
Return of common stock for service		–		–			–		–		(50,000,000	)		–		(30,000	)		–			(30,000	)
Net loss		–		–			–		–		–			–		–			(548,820	)		(548,820	)
Balance - May 31, 2025		2,500,000	$	–			2,000	$	–		11,626,749,347		$	–	$	4,719,318		$	(5,882,901	)	$	(1,163,583	)

The accompanying notes are an integral part of these consolidated financial statements.

F-5

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.

(formerly named China Infrastructure Construction Corp.)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

May 31, ~~2024~~2025

Note 1 – Organization and Business

Organization and Operations

Cannabis Bioscience International Holdings, Inc., a Colorado corporation (the “Company”), was formed on February 28, 2003, as a limited liability company ~~named~~under ~~Fidelity~~the ~~Aircraft~~name Fidelity Aircraft Partners LLC. On December 16, ~~2004~~2009, it converted to a corporation under the name Fidelity Aviation Corporation, and on August 24, 2009, it changed its name to China Infrastructure Construction Corp. On February 28, 2018, the Company changed its name to Hippocrates ~~Direct~~ Direct Healthcare, Inc.; on July 4, 2018, it resumed the name China Infrastructure Construction Corp. On December 6, 2022, it changed its name to its present name. The Company provides educational systems focused on medical cannabis in ~~cities throughout~~ the United States; ~~and~~provides ~~six~~services ~~countries~~to inthird ~~Latin~~parties ~~America. The Company provides services~~ in therapeutic areas of clinical; ~~trials~~ and ~~services~~is ~~relating~~developing ~~to sleep disorders through its sleep center in Houston, Texas. The Company offered concierge medicine at an affordable price through a membership~~cannabidiol-based model through its wholly owned subsidiary, Hippocrates Direct Healthcare, LLC, a Texas limited liability company, formed on September 11, 2017; this business was discontinued during the quarter ended August 31, 2020products. The Company operated a sleep center, which diagnosed sleep-related disorders, through its subsidiary, Alpha Fertility and Sleep Center, LLC, a Texas limited liability company; its operations were terminated on April 30, 2023.

Note 2 – Summary of Significant Accounting Policies

Accounting Principles

The financial statements and notes thereto have been prepared by management using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and ~~expenses~~ expenses during the reporting periods. Making estimates requires management to exercise significant judgment. Certain of these estimates ~~could~~ could be affected by external conditions, including those unique to the Company’s businesses, and general economic conditions. These ~~external~~ external conditions could ~~have~~affect ~~an effect on~~ the Company’s estimates that could cause actual results to differ materially from its estimates. Actual results could differ from those estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and records adjustments when necessary. Significant estimates relied upon in preparing these statements include revenue recognition, accounts receivable reserves, accrued expenses, share-based compensation and the recoverability of the Company’s net deferred tax assets and any related valuation allowance.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

F-6

Reclassification

Certain amounts in the prior consolidated financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no impact on the results of operations, changes in equity, or cash flows.

Cash and Cash Equivalents

Cash equivalents are short-term, highly liquid investments that are readily convertible to cash with original maturities of three months or less at the ~~date~~time ~~acquired~~of acquisition. The Company ~~had~~ nohad zero investment securities that were deemed cash equivalents at May 31, ~~2024~~2025, and May 31, ~~2023~~2024, respectively.

Accounts Receivable

Included in accounts receivable on the balance sheets are amounts primarily related to customers. The Company estimates losses on receivables based on known troubled accounts and historical experience of losses incurred. Receivables are considered impaired and written off when it is probable that all contractual payments due will not be collected in accordance with the terms of the related agreement. Based on experience and the judgment of management, there was no allowance for doubtful accounts at May 31, ~~2024~~2025, and May 31, ~~2023~~2024.

F-6

Revenue Recognition

The Company follows the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), as amended. This standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that it expects to receive for them.

Under ASU No. 2014-09, the Company recognizes revenue when a customer obtains control of promised goods or services, or when they are shipped to a customer, in an amount that reflects the consideration that it expects to receive in exchange for them. The Company recognizes revenues following the five-step model prescribed under ASU No. 2014-09: (a) it identifies a contract with a customer; (b)  it identifies the performance obligations in the contract; (c) it determines the transaction price; (d) it allocates the transaction price to the performance obligations in the contract; and (e) it recognizes revenues when (or as) it satisfies its performance obligation.

The Company generates revenue from multiple streams, namely, clinical trials, consulting fees, seminars and merchandise sales. Revenues from product sales are recognized when a customer obtains control of the Company’s product, which occurs at a point in time or over time, typically upon shipment to the customer or when services are fulfilled and the customer receives benefit from such services. Revenue is deferred and a liability is established to the extent that the Company receives payments from customers in advance of goods being shipped or services being rendered.

The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset in which it would have been recognized is one year or less or the amount is immaterial.

A performance obligation is a contractual promise to transfer a distinct product or service to a customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Each contract has a single performance obligation as the promise to transfer the individual goods or services is not separately identifiable from other promises in the contracts and, therefore, not distinct. Revenue from contracts that satisfy the criteria for overtime recognition is recognized as the work progresses. The majority of the Company’s revenue is derived from services provided to customers and is ~~executed~~ typically executed over a period ~~that~~of ~~is typically~~ between 1 toand 12 months, based on evaluation of when these services are rendered. Contracts will continue to be recognized over time because of the continuous transfer of control to the customer as services are rendered to customers. ~~Payments~~ Payments made by customers in advance of services being rendered are recorded as deferred revenue.

FOur significant payment terms for customer contracts vary based on the revenue stream. Contracts for clinical trials typically provide for progress payments based on the number of patients seen, with final payments generally due within 30 days upon completion of work or the termination of the contract. Revenue is recognized when all performance obligations under the terms of a contract are satisfied. The Company requires advance payments from its consulting customers and these payments are recorded as contract liabilities on the consolidated balance sheet until service is performed and revenue is recognized. These advance payments are not treated as a financing component based on the guidance in ASC 606-710-32-196-16 and -17, whereby the timing of when services are provided is at the discretion of the customers or a substantial amount of the consideration promised by the customer is variable and not in the control of the customer or the Company. There is no significant financing component to any of the Company’s contracts.

~~Our significant~~Contracts ~~payment terms~~ for ~~customer~~educational ~~contracts~~services ~~vary~~require ~~based~~non-refundable onpayment the revenue stream. Franchising business clients are required to advance a percentage of the franchise fee upon acceptance of the contract. These advances, when received, are accounted for as contract liabilities on the consolidated balance sheet and are subsequently recognized in revenue when they are earned. Contracts for clinical trials typically provide for progress payments based on the number of patients seen, with final payments generally due within 30 days upon completion of work or the termination of the contract. Revenue is recognized when all performance obligations under the terms of a contract are satisfied. The Company requires advance ~~payments from its consulting customers~~ and ~~these payments~~ are recorded as ~~contract liabilities on the consolidated balance sheet until service is performed and~~ revenue ~~is recognized. These advance payments are not treated as financing components based on the guidance in ASC 606-10-32-196-16 and -17, whereby the timing of~~ when ~~services are provided is at the discretion of the customers or a substantial amount of the consideration promised by the customer is variable and not in the control of the customer or the Company~~received.

Contracts for educational services require nonrefundable payment in advance and are recorded as revenue when received.

There is no significant financing component to any contracts.

F-7

Contract Modifications

Contracts for the Company’s clinical trial business are subject to modification. These modifications may create new, or change existing, enforceable rights and obligations of the parties thereto. Modifications are generally effected pursuant to an amendment or addendum to the original contract. A contract modification is accounted for as a new contract if it reflects an increase in scope that is regarded as distinct from the original contract and is priced in line with the standalone price for the related services. If a contract modification is not considered a new contract, the modification is combined with the original contract and the impact on revenue recognition will depend on whether the remaining services are distinct from the original contract. If they are distinct from those in the original contract, all remaining performance obligations will be accounted for on a prospective basis, with unrecognized consideration allocated to the remaining performance obligations. If the remaining goods or services are not distinct, the modification will be treated as if it were a part of the existing contract and the effect that the contract modification has on the transaction price and the measure of progress toward satisfaction of the performance obligations are recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification on a cumulative catch-up basis.

Remaining Performance Obligations

The Company follows ASC 606, which requires the allocation of the transaction price to the remaining performance obligations of a contract and applies a practical expedient allowing it not to disclose the amount of the transaction price allocated to the remaining performance obligations for contracts with an original expected duration of one year or less. As of May 31, ~~2024~~2025, and May 31, ~~2023~~2024, the Company had no remaining performance obligations.

Share-Based Payments

ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions. In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which aligns accounting for share-based payments issued to non-employees to that of employees under the existing guidance of Topic 718, with certain exceptions. This update supersedes previous guidance for share-based payments to non-employees under Subtopic 505-50, Equity – Equity-Based Payments to Non-Employees. This guidance became effective for the Company on January 1, 2019. Based on its completed analysis, the Company has determined that adopting this guidance will not have a material impact on its financial statements. The Company follows FASB guidance related to equity-based payments, which requires that equity-based compensation be accounted for using a fair value method and recognized as expense in the accompanying statements of operations. Equity-based compensation expense will be recognized as compensation expense.

F-8

Leases

The Company has adopted ASU 2016-02, Leases (Topic 842), along with related clarifications and improvements, under which lessees are required to recognize a lease liability, which represents the discounted obligation to make future minimum lease payments and a corresponding right-of-use asset on the balance sheet for most leases. The guidance retains the historical accounting for lessors and does not make significant changes to the recognition, measurement, and presentation of expenses and cash flows by a lessee. Enhanced disclosures are also required to give financial statement users the ability to assess the amount, timing and uncertainty of cash flows arising from leases.

Cash Flows

The Company follows ASU 2016-18, “Statement of Cash Flows (Topic 230),” requiring that the statement of cash flows explain the change in the total cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The provisions of this guidance are to be applied using a retrospective approach, which requires the application of the guidance for all periods presented.

F-8

Fair Value Measurements

The Company has adopted ASC Topic 820, Fair Value Measurements, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair-value measurements. 

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, is carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of the Company’s short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features, such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.

ASC Topic 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC Topic 820 also establishes a fair-value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC Topic 820 describes three levels of inputs that may be used to measure fair value:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Quoted prices for similar assets and liabilities in active markets or inputs that are observable.

Level 3: Inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).

Income Taxes

 The Company accounts for income taxes in accordance with Accounting Standards Codification No. 740, “Income Taxes” (“ASC 740”). This codification prescribes the use of the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and for carryforward tax losses. Deferred taxes are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that some portion or all of the deferred tax asset will not be realized.

F-9

 Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting or according to the expected reversal dates of the specific temporary differences, if not related to an asset or liability for financial reporting.

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740, which provides guidance as to the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in its ~~unaudited~~ financial statements, under which a company may recognize the tax benefit ~~from~~ from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.

The tax benefits recognized in financial statements from such a position are measured based on the largest benefit that has a greater than  50% likelihood of being realized upon ultimate settlement. Accordingly, the Company would report a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. The Company elects to recognize ~~any~~ interest and penalties, if any, related to unrecognized tax ~~benefits~~ benefits in tax expense.

Loss per Share

The Company computes basic earnings per share amounts in accordance with Accounting Standards Codification Topic 260,  “Earnings per Share.”  Basic earnings per share is calculated by dividing net income (loss) available to common stockholders by the weighted average number of common shares ~~outstanding~~ outstanding during the reporting period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. At May 31, ~~2024~~2025, and May 31, ~~2023~~2024, the Company had no dilutive securities.

F-9

Recently Issued Accounting Standards

The Company does not believe there are any other recently issued, but not yet effective, accounting standards that would have a significant impact on the Company’s financial position or results of operations.

Note 3 – Going Concern

The accompanying audited financial statements have been prepared in conformity with U.S. GAAP, which contemplates the Company’s continuation as a going concern in accordance ~~with~~ with ASC 240-40-50. The Company’s history of recurring losses, negative working capital and negative cash flows from operating activities raises substantial doubt about its ability to continue as a going concern. The Company has not generated any profits since ~~inception~~its ~~and~~inception, and its current cash balances will not meet its working capital needs. At May 31, ~~2024~~2025, the Company had aan ~~net~~operating loss ~~from~~of ~~operations~~$421,365, a net loss of $~~486~~548,~~140~~820, net cash used in operations of $~~479~~329,~~382~~627, a working capital deficit of $~~860~~916,~~417~~878 and an accumulated deficit of $5,~~334~~882,~~081~~901.

The ability of the Company to continue as a going concern depends on the successful execution of its operating plan, which includes expanding its operations and raising either debt or equity financing. There is no assurance that the Company will be able to expand its operations or obtain such financing on satisfactory terms or at all. If the Company is unsuccessful in these endeavors, it may be required to curtail or cease its operations.

The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

F-10

Note 4 – Debt

~~EIDL~~Long-Term Debt – SBA Loans

In May 2020, the Company ~~received~~borrowed $143,100 ~~from~~ from the Small Business Administration (the “SBA”) as an Economic Injury Disaster Loan (“EIDL”) to help fund its operations during the COVID-19 pandemic. The loan bears interest at the rate of 3.75% per annum and is payable in monthly installments of $698 for ~~over~~ a 30-year ~~period,~~ ~~with deferral of payments for the first 12 months~~period.

In June 2020, the Company ~~received proceeds of~~borrowed $106,200 from the ~~Small~~SBA ~~Business Administration~~ through a second EIDL loan to help fund its operations during the COVID-19 pandemic. The loan bears interest at the rate of 3.75% per annum and is payable in monthly installments of $518 ~~over~~for a 30-year period.

~~The~~These ~~Company’s EIDL~~ loans ~~were~~are recorded in as long-term debt in the consolidated balance sheet as follows:

Schedule of EIDL loans
	May 31,
	2024		2023
	2025		2024
SBA (EIDL) current portion	$	714,~~054~~592	$	147,~~592~~054
SBA (EIDL) noncurrent portion		249,~~361~~500		249,~~500~~361
Total EIDL loans	$	256,415	$	264,092
Accrued interest		22,095		–
Total EIDL loans	$	286,187	$	256,415

~~Short-Term~~The ~~Loans~~accrued interest shown in the above table is presented as accrued interest in the consolidated balance sheets.

The Company has borrowed money and entered into agreements under which it sold receivables to third parties. In accordance with ASC 470, these agreements are treated as loans encumbering the receivables of the Company in the event of default and are accounted for as a debt, such that payments are allocated to principal and interest expense as they are made. These borrowings and agreements are as follows:F-10

·Short-Term In May 2022, the Company entered into a financing agreement with an unrelated party for a loan of $50,000 at an annual interest rate of 20.9%, to be repaid at the rate of $1,218 per week for one year. At May 31, 2024, the balance of this loan, including interest, was $54,029. Payments under this agreement are in arrears and the Company is negotiating with the unrelated party to reschedule them. · In January 2023, the Company entered into a financing agreement with an unrelated party for a loan of $20,000, bearing interest at the rate of 33.5% per annum, to be repaid at the rate of $1,874 per month. The outstanding balance at May 31, 2024, was $1,674. Payments under this agreement are in arrears and the Company is negotiating with the unrelated party to reschedule them. · In April 2023, the Company entered into a financing agreement with an unrelated party for a loan of $37,475, bearing interest at the rate of 19% per annum, to be repaid at the rate of $1,718 per month. The outstanding balance at May 31, 2024, was $26,300. Payments under this agreement are in arrears and the Company is negotiating with the unrelated party to reschedule them. · On August 8, 2022, the Company entered into a financing agreement (the “AF Agreement”) with an unrelated party for a loan of $45,000 at an annual interest rate of 26.4%, to be repaid at the rate of $6,114 per week for 20 weeks, On October 17, 2022, this loan was refinanced to include an additional $10,000, such that it bears interest at an annual interest rate of 26.4%, to be repaid at the rate of $3,057 per week for four weeks. On December 20, 2022, the loan was increased to $76,000 and the financing agreement was modified such that the loan bears interest at an annual interest rate of 26.4% and is to be repaid at the rate of $6,114 per week for 17 weeks. The balance of this loan at May 31, 2024, including interest, was $38,638. Payments under this agreement are in arrears and the Company is negotiating with the unrelated party to reschedule them.Debt

Non-Convertible Loans and Financing Agreements

The Company has entered into loans under which it borrowed money and financing agreements under which it sold receivables to third parties. In accordance with ASC 470, the financing agreements are treated as loans encumbering the receivables of the Company in the event of default and are accounted for as indebtedness, such that payments are allocated to principal and interest expense as they are made. These transactions are as follows:

In May 2022, the Company entered into a financing agreement with an unrelated party for a loan of $50,000, bearing interest at the rate of 20.9% per annum, to be repaid at the rate of $1,218 per week for one year. At May 31, 2025, the outstanding balance, including interest, was $55,422. This loan is in default.

In January 2023, the Company entered into a financing agreement with an unrelated party for a loan of $20,000, bearing interest at the rate of 33.5% per annum, to be repaid at the rate of $1,874 per month. The outstanding balance at May 31, 2025, was $2,921. Payments under this agreement are in arrears and the Company is negotiating with the unrelated party to reschedule them.

In April 2023, the Company entered into a financing agreement with an unrelated party for a loan of $37,475, bearing interest at the rate of 19% per annum, to be repaid at the rate of $1,718 per month. The outstanding balance at May 31, 2025, was $35,508. Payments under this agreement are in arrears and the Company is negotiating with the unrelated party to reschedule them.

On August 8, 2022, the Company entered into a financing agreement with an unrelated party for a loan of $45,000, bearing interest at the rate of 26.4% per annum, to be repaid at the rate of $6,114 per week for 20 weeks. As refinanced, the loan was increased to $76,000 at the same rate of interest and was to be repaid at the rate of $6,114 per week for 17 weeks. On May 13, 2024, the Company agreed to settle the $38,638 owing under this agreement in consideration of a payment of $15,000, which the Company made on June 12, 2024. Under ASC 470-50-40, the fair value of extinguished debt, less the fair value of the payment, is treated as gain. Accordingly, $23,638 is recorded in the Company’s consolidated statement of operations as Other income (Expense) – Forgiveness of debt.

On October 8, 2019, the Company borrowed $12,500 from an unrelated party bearing interest at the rate of 14% per annum (the “Headway Loan”). This loan is payable at the weekly rate of $589 for 24 weeks. On October 13, 2022, an additional loan of $6,304 was obtained with a weekly payment of $297 for 24 weeks. The loan was guaranteed by a related party. At May 31, 2025, the outstanding balance of this loan, including interest, was $16,871. This loan is in default.

F-11

	·	On June 29, 2022, the Company borrowed $12,500 from an unrelated party at an annual interest rate of 14%. This loan is payable at the weekly rate of $589 for 24 weeks. On October 13, 2022, an additional loan of $6,304 was obtained with a weekly payment of $297 for 24 weeks. At May 31, 2024, the balance of this loan, including interest, was $15,073. Payments under this loan are in arrears and the Company is negotiating with the unrelated party to reschedule them.
	·	On August 3, 2022, the Company borrowed $15,000 from an unrelated party at an annual interest rate of 42.5%, repayable at the rate of $1,188 per month for 18 months. At May 31, 2024, the balance of this loan, including interest, was $15,553. Payments under this loan are in arrears and the Company is negotiating with the unrelated party to reschedule them.

Convertible Notes

~~See~~The ~~Note~~Company 11has ~~for~~borrowed ~~information~~money ~~regarding~~under a promissory notes ~~note~~that ~~made~~have byconvertibility ~~the~~features ~~Company~~as infollows: ~~favor of a related party and cash advances made during the year ended May 31, 2024, by the officers of the Company.~~

On March 14, 2024, the Company made a promissory note in the principal amount of $66,000 in favor of an unrelated party. The note was subject to an original issuance discount of $11,000 and to an initial interest charge of 13% of its principal amount, or $8,580. The net proceeds received by the Company after the original issuance discount, the initial interest charge and payment of legal and due diligence fees of $5,000, were $50,000. The note required repayment in five installments, as follows: a payment of $37,290 on September 15, 2024, and payments of $9,322.50 on October 15, 2024, November 15, 2024, December 15, 2024, and January 15, 2025. Each of these payments included accrued interest. The note was repaid on January 12, 2025, at which time, it was not in default. The note provided that upon an event of default, the holder could convert the amount then unpaid into Common Stock at a conversion price of 65% of the lowest trading price therefor during the 10 trading days prior to the date of conversion.

On November 7, 2024, the Company made a promissory note in the principal amount of $67,200 in favor of an unrelated party (the “Diagonal Note”). The note is subject to an original issuance discount of $11,200. The net proceeds received by the Company after payment of legal and due diligence fees of $6,000, were $56,000. The note requires repayment in five installments, as follows: a payment of $37,968 on May 15, 2025, and payments of $9,492 on June 15, 2025, July 15, 2025, August 15, 2025, and September 15, 2025. Each of these payments includes accrued interest. The note provides that upon an event of default, the holder may convert the amount then unpaid into Common Stock at a conversion price of 65% of the lowest trading price therefor during the 10 trading days prior to the date of conversion. At May 31, 2025, the unpaid amount of the note was $32,228.

The Company determined that the above convertible notes contained an embedded derivative instrument, inasmuch as the conversion price was based on a variable that was not an input to the fair value of a “fixed-for-fixed” option, as defined under FASB ASC Topic No. 815–40. The Company determined the fair values of the embedded convertible note derivatives contained in the convertible notes using the Black Scholes option pricing model.The conversion features of these notes have been accounted for as a derivative liability in the Consolidated Statements of Operations – Change in fair value of derivative liabilities.

Related Party Debt

For information about related party debt, see Note 11 – Related Party Transactions – Loans and Advances.

F-12

Note 5 – Right-of-Use Assets and Lease Liabilities

The Company leases real property from unrelated parties under leases that are classified as operating leases. The right-of-use assets for operating leases are included in the right-of-use assets onsection of the balance ~~sheets~~sheet, with the corresponding lease liability listed in the liabilities section. Lease expense is recognized on a straight-line basis over the lease term. Renewals and terminations are included in the calculation of right-of-use assets and lease liabilities when they are considered reasonably ~~certain~~sure to be exercised. When the implicit rate is unknown, the incremental borrowing rate, based on the commencement date, is used in determining the present value of lease payments. During the Fiscal Year 2025, the company reduced its total office area lease and signed a one-year lease from an unrelated party. A lease term of 12 months or less qualifies as a short-term lease, and an exemption was elected.

The following amounts ~~related~~ relate to ~~leases~~right-of-use ~~were~~assets ~~recorded~~and lease liabilities presented in the balance sheets:

Schedule of leases
Schedule of amount related to leases
	May 31,
	2024			2023
	2025			2024
Right-of-use asset	$	432,~~150~~795		$	~~155~~43,~~387~~150
Less: Accumulated amortization		~~(7,480~~–	)		(~~131~~7,~~467~~480	)
Right-of-use asset, net	$	352,~~670~~795		$	2335,~~920~~670
Lease liabilities – current	$	214,~~877~~906		$	421,~~435~~877
Lease liabilities – noncurrent		~~4,906~~–			–4,906
Operating lease liabilities	$	264,~~873~~906		$	426,~~435~~873

The Company reimburses related parties for an office space operating lease under a month-to-month arrangement, payable at the discretion of management. See Note 10.

The Company’s total operating lease expense ~~expenses~~was ~~were~~ $8665,~~730~~ 301 and $7186,~~942~~ 730 during the years ended May 31, ~~2024~~2025, and May 31, ~~2023~~2024, respectively. See Note 10 for additional lease information.

Note 6 -- Revenue

Most of the Company’s revenue is generated by the performance of services to customers and recognized at a point in time based on the evaluation of when the customer obtains control of the products. Revenue is recognized when all performance obligations under the terms of a contract are satisfied, net of certain taxes ~~and gain/loss resulting from changes in foreign currency~~. Revenue is recorded when customer acceptance is received and all performance obligations have been satisfied. Sales of goods typically do not include multiple products and/or service elements.

F-12

The table below summarizes the Company’s disaggregated revenue information:

Schedule of disaggregated revenue
	Year Ended May 31,
	2024		2023
	2025		2024
Clinical trials	$	~~213~~301,~~865~~731	$	~~267~~213,~~220~~865
Consulting fees		~~28,641~~–		828,~~333~~641
Video Course		–		2,497
Seminar fees		–		1,925
Seminar fees		1,925		16,433
Merchandise		1,291		4,410
Royalty		–		42
Total revenue	$	303,022	$	248,841
Merchandise		4,410		22,300
Total revenue	$	248,841	$	316,825

Cost of revenue consists of third-party costs associated with the patient ~~stipends,~~stipend ~~sleep study fees~~ and audio/video fees. At May 31, ~~2024~~2025, and May 31, ~~2023~~2024, cost of revenue totaled $4540,~~599~~106 and $9345,~~450~~599, respectively.

~~Note 7 – Stockholders’ Deficiency~~F-13

~~The~~Note ~~Company~~7 is– ~~authorized~~Stockholders’ ~~to issue 20,010,000,000 of capital stock, of which 20,000,000,000 shares are Common Stock, without par value, and 10,000,000 are preferred stock, issuable in series.~~Deficit

The Company is authorized to issue 20,010,000,000 shares of capital stock, of which 20,000,000,000 shares are common stock, without par value, and 10,000,000 shares are preferred stock, issuable in series.

Preferred Stock

The Company has designated  2,500,000  shares of of preferred stock as Series A Convertible Preferred Stock (the “Series A Stock”). Until July 20, 2022, each share had a par value of $0.001; on that date, the Company amended its articles of incorporation to provide that each such share has no par value. Under this amendment, (i) Series A Stock is entitled to receive dividends on the shares of ~~Common~~common ~~Stock~~stock into which such shares are convertible, (ii) has the voting power of the number of shares of ~~Common~~common ~~Stock~~stock into which such shares are convertible, (iii) is redeemable at the option of the Company for a redemption price equal to the number of shares of Common Stock into which the redeemed shares are convertible and (iv) are senior to the ~~Common~~common ~~Stock~~stock and junior to the Series B Convertible Preferred Stock described below. At May 31, ~~2024~~2025, and May 31, ~~2023~~2024, there were  2,500,000  shares of Series A Stock issued and outstanding.

On July 20, 2022, the Company designated a series of preferred stock, named Series B Preferred Convertible Preferred Stock, comprising  1,000  shares (“Series B Preferred”). The shares of this series have  no  par value, are not entitled to dividends, have no liquidation rights, are not redeemable, are not convertible, have 60% of the Company’s voting power and rank senior to the ~~Common~~common ~~Stock~~stock and Series A Convertible Preferred Stock. The  1,000  preferred shares were issued in exchange for common stock to an existing holder of Common Stock, towho is a related party. The Company has deemed the value of the preferred and common shares to be the same, resulting in no change to additional paid-in capital. At May 31, ~~2024~~2025, and May 31, ~~2023~~2024, there were 1 2,000  shares of Series B Preferred issued and outstanding.

Common Stock

During the year ended May 31, ~~2024~~2025, the Company sold ~~272~~575,~~071~~000,~~428~~000 shares of Common Stock for $70158,000 and during the year ended May 31, ~~2022~~2024, the Company sold 2272,~~042~~071,~~146,825~~428 shares of Common Stock for $~~801~~70,~~966~~000.

During the year ended May 31, ~~2024~~2025, the Company issued 325,000,000 shares of Common Stock for services rendered; these shares had a market value of $250,000 on the date of their issuance. In that year, the Company retired 50,000,000 shares of Common Stock that had been issued for services that were not unperformed, valued at $30,000. During the year ended May 31, 2024, the Company issued 100,000,000 shares of Common Stock for services rendered.; ~~These~~these shares had a market value of $75,000 on the date of their issuance.

AtDuring ~~May~~the ~~31,~~year ~~2024,~~ended ~~and~~ May 31, ~~2023~~2025, ~~respectively,~~ ~~there~~the ~~were~~Company ~~10,431,749,347 and~~issued 10345,~~059~~000,~~677,919~~000 shares of Common Stock ~~issued~~to ~~and~~an ~~outstanding~~unrelated party in consideration of a promissory note in the principal amount of $86,250.

~~F-13~~On May 31, 2025, and May 31, 2024, there were, respectively, 11,626,749,347 and 10,431,749,347 shares of Common Stock issued and outstanding.

Note 8 – Share-Based Compensation

On July 20, 2022, the Company adopted its 2022 Equity Incentive Plan, which provides for the grant of incentive and non-statutory stock options, stock appreciation rights, restricted stock, unrestricted stock, restricted stock units and performance awards to directors, officers, employees and consultants, as determined by the Board, as plan administrator. The Company will recognize as share-based compensation expense all share-based payments to employees over the requisite service period (generally the vesting period) in its consolidated statements of operations based on the fair values of the awards that are issued.

F-14

Note 9 – Income Taxes

The Company provides for income taxes under ASC 740. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax basis of assets and liabilities and the tax rates in effect when these differences are expected to reverse. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. 

On December 22, 2017, the 2017 Tax Cuts and Jobs Act (the “Tax Act”) was enacted into law, making significant changes to the Code. These changes included a federal corporate tax rate decrease from  35% to  21% for tax years beginning after December  31, 2017, the transition of U.S. international ~~taxation~~ taxation from a worldwide tax system to a territorial system and a one-time transition tax on the mandatory deemed repatriation of foreign earnings. The Company is required to recognize the effect of the tax law changes in the period of enactment, such as re-measuring its U.S. deferred tax assets and liabilities, as well as reassessing the net realizability of its deferred tax assets and liabilities. The Tax Act did not ~~give~~ ~~rise~~have toa ~~any~~ material impact on the balance sheets and statements of operations, ~~due~~given to the Company’s historical worldwide ~~loss~~ loss position and the full valuation allowance on its net U.S. deferred tax assets. The ~~reconciliation~~current oftax ~~taxes at the federal and state statutory~~ rate toon ~~the~~corporate ~~Company’s provision for~~ income ~~taxes~~is ~~for the years ended May 31, 2024, and May 31, 2023, was as follows:~~21%.

Schedule of provision for income taxes
	May 31, 2024
Income tax expense (benefit) at the statutory rate	$	1,120,157
Valuation allowance		(1,120,157	)
Income tax expense per books	$	–

Due to changes in ownership provisions of the United States income tax laws, net operating loss carryforwards of approximately $5,882,901 and $5,334,081 at May 31, 2025, and May 31, 2024, respectively, for federal income tax reporting purposes are subject to annual limitations. When a change in ownership occurs, the use of net operating loss carryforwards may be limited in future years. They generally expire 20 years from the date of incurrance.

	May 31, 2023
Income tax expense (benefit) at the statutory rate	$	979,658
Valuation allowance		(979,658	)
Income tax expense per books	$	–

The Company’s income tax benefits are calculated by applying the U.S. Federal statutory rate of 21% to net income (loss). The tax effects of the benefits that gave rise to the Company’s net deferred tax assets at May 31, 2025, and May 31, 2024, were as follows:

Due to changes in ownership provisions of the income tax laws of the United States of America, net operating loss carryforwards of approximately $5,334,081 and $4,682,736 at May 31, 2024, and May 31, 2023, respectively, are subject to annual limitations for federal income tax reporting purposes. When a change in ownership occurs, the use of net operating loss carryforwards may be limited in future years. They generally expire 20 years from when incurred.

	Year Ended May 31,
	2025			2024
Net operating loss carryforward	$	1,235,409		$	1,120,157
Less: valuation allowance		(1,235,409	)		(1,120,157	)
Deferred tax assets -net	$	–		$	–

Income taxes for 2017 to ~~2024~~2025 remain subject to examination by the Internal Revenue Service.

F-14

Note 10 – Commitments and Contingencies

The Company ~~leased~~leases premises of approximately 4,500 square feet located at 6201 Bonhomme Road, Suites 460S and 466S, Houston, Texas. The lease provided for a base rent of $3,382  per month, increasing to (i)  $3,529  per month on July 1, 2020, (ii) $3,676.04 per month on July 1, 2021, and (iii)  $3,823  per month on July 1, 2022, subject to CPI increase.  On March 23, 2023, the Company amended the lease to extend its term to June 30, 2024, at a base rent of $4,779 per month. ~~For~~On September ~~information~~5, ~~regarding~~2023, the ~~recording~~lease ofwas ~~the~~amended ~~right-of-use~~to ~~asset~~extend ~~and~~its ~~the~~term ~~lease~~to ~~liability~~June in30, ~~the~~2025, ~~balance~~at ~~sheets~~rentals ~~with~~of ~~respect~~$0 toper ~~this lease,~~month ~~see~~for ~~Note~~the 5.two ~~This~~months ~~lease~~ended ~~was~~February ~~terminated effective May 1~~29, 2024, ~~and~~$$4,779 onper ~~that~~month ~~date,~~for the ~~Company~~10 ~~leased~~months ~~premises~~ending ofJune ~~approximately 1~~30,~~367~~ ~~square~~2024, ~~feet~~and ~~located~~$4,926 atper ~~6201~~month ~~Bonhomme~~for ~~Road,~~the ~~Suite~~12 ~~435N,~~months ~~Houston,~~ending ~~Texas~~June 30, ~~under~~2025.  This a lease ~~dated~~was ~~April~~amended ~~12,~~on ~~2024.~~June ~~This~~18, ~~lease~~2025, ~~which has~~to add a one-year term that commenced on ~~May~~June 1, ~~2024~~2025, ~~provides~~at ~~for~~a base rent of $1,~~631~~730 per month. For information regarding the recording of the right-of-use asset and the lease liability in the consolidated balance sheets in respect of this lease, see Note 5.

Two of the Company’s officers leased 1,400 square feet ~~in Houston, Texas,~~ at 1625 Main St., Houston, Texas, under a lease the term of which commenced on March 15, 2023, and expired on September 14, 2023, at a rent of $3,168 per month. These officers made a portion of these premises available to the Company for ~~use~~ as office space, for which the Company paid them $2,817 per month. These officers entered into a new lease for these premises, which ~~commenced~~ commenced on September 15, 2023, and ~~will~~expired ~~expire~~ on September 14, 2024, at a rent of $3,164 per month and they made a portion of these premises available to the Company for use as office space, for which the Company paid them $2,817 per month. On September 3, 2024, one of the Company’s officers entered into a new lease for these premises. The term of the lease began on September 15, 2024, and expired on August 14, 2025. The lease has not been renewed and under its terms, it has been renewed on a month-to-month basis. The officer has made a portion of these premises available to the Company for use as office space, for which the Company ishas ~~paying~~paid ~~them~~him $2,817 per month.

F-15

Note 11 – Related Party Transactions

See Note 108 ~~for~~– ~~information~~Stockholders’ ~~respecting~~Deficiency – ~~the~~Common ~~lease of~~Stock ~~real~~for ~~property~~information toabout the ~~Company~~issuance byof ~~two~~shares of ~~its~~common ~~officers~~stock to a related party.

OnSee ~~April~~Note ~~26,~~10 ~~2024,~~for ~~the~~information ~~Company~~respecting ~~made a promissory note in~~ the ~~principal~~lease ~~amount~~ of ~~$291,451~~real inproperty ~~favor of a related party. This note matures on April 25, 2025, bears interest at the rate of 10% per annum and is repayable in 10 monthly installments of $29,145. Events of default include failure~~ to ~~pay principal or interest when due, breach of covenant, breach of representation and warranty, assignment for~~ the ~~benefit~~Company ~~of creditors or appointment of a receiver, bankruptcy and cessation of operations. The Jones Note replaces promissory notes previously made~~ by ~~the~~one ~~Company in favor~~ of ~~the~~its ~~related party~~officers.

~~During~~The ~~the~~Headway ~~year~~Loan ~~ended~~(see ~~May~~Note ~~31,~~4) ~~2023,~~was ~~the~~guaranteed ~~Company~~by ~~received~~a ~~cash advances from~~ related ~~parties of $101,335 for use as working capital~~party.

On August 3, 2022, the Company borrowed $15,000 from a related party. This loan is undocumented. The ~~balance~~understanding ofbetween the Company and the related party ~~liabilities~~is ~~outstanding~~that it would make payments tounder ~~certain~~the ~~shareholders~~note ~~totaled~~as ~~$503~~they became due. In the year ended May 31,~~214~~ 2024, the Company ceased making such payments. This note bears interest at the rate of 42.5% per annum and is to be repaid at the rate of $~~105~~1,~~173~~188 per month for 18 months. The Company believes that, at May 31, ~~2024~~2025, ~~and~~the ~~May~~outstanding 31balance of this loan, ~~2023~~including interest, ~~respectively~~was $16,465 and that it is in default or has been written off by the lender.

On May 1, 2025, the Company made a promissory note in the principal amount of $340,855 in favor of John Jones and Barbara Kamienski (the “Jones Note”). This note bears interest at the rate of 2.5% per annum and is repayable in monthly installments of $8,521, beginning on May 31, 2025, until paid in full. Events of default included failure to pay principal or interest when due, breach of covenant, breach of representation and warranty, assignment for the benefit of creditors or appointment of a receiver, bankruptcy and cessation of operations. The Jones Note replaces promissory notes previously made by the Company in favor of Mr. Jones and Ms. Kamienski.

On April 26, 2024, the Company made a promissory note in the principal amount of $291,451 in favor of a related party, which had a maturity date of April 25, 2025, bore interest at the rate of 10% per annum and was repayable in 10 monthly installments of $29,145. Events of default include failure to pay principal or interest when due, breach of covenant, breach of representation and warranty, assignment for the benefit of creditors or appointment of a receiver, bankruptcy and cessation of operations. This note replaced promissory notes previously made by the Company in favor of the related party. This note was replaced by the Jones Note.

During the year ended May 31, 2025, and the year ended May 31, 2024, the Company received cash advances from related parties of $61,861 and $81,552, respectively, for use as working capital.

The balance of related party liabilities owed to certain shareholders totaled $623,474 and $518,287 at May 31, 2025, and May 31, 2024, respectively. The balance of related party receivables owed by certain shareholders totaled $9,155 and $0 at May 31, 2025, and May 31, 2024, respectively.

Note 12 – Off-Balance-Sheet Arrangements

The Company has no off-balance sheet arrangements.

Note 13 – Concentration of Risk

The Company had revenue, net of ~~$248~~taxes,~~841~~ of $303,022 and $~~316~~248,~~825~~841 for the years ending May 31, ~~2024~~2025, and May 31, ~~2023~~2024, respectively.

The Company had two customers that provided 8291% of gross revenue for the year ended May 31, ~~2024~~2025, and ~~three~~two customers that provided 8482% of gross revenue for the year ended May 31, ~~2023~~2024.

Note 14 – Subsequent Events

InOn ~~previous~~September ~~years~~10, ~~the~~2025, ~~COVID-19 pandemic had a material adverse effect on~~ the Company’s ~~educational~~issued ~~business~~100,000,000 shares ~~because~~of ~~governmental~~Common ~~measures~~Stock ~~that we imposed~~ to ~~control~~John ~~it resulted~~Jones in ~~the~~consideration ~~closing~~ of ~~classrooms~~his ~~and~~services ~~other~~as ~~educational~~a ~~venues, and also hindered the Company’s franchising and consulting activities~~director. ~~The Company believes that its operations are no longer affected by the pandemic.~~

~~F-15~~On September 5, 2025, the Company made the last payment of $9,492 under the Diagonal Note.

On May 13, 2024, the Company agreed to settle $38,638 owing under the AF Agreement in consideration of a payment of $15,000, which the Company made on June 12, 2024. Under ASC 470-50-40, the fair value of extinguished debt, less the fair value of the payment, is to be treated as gain. Accordingly, $23,638 will be recorded in the Company’s consolidated statement of operations for the quarter ended August 31, 2024, as Other Income – Forgiveness of Debt.

On August 11, 2024, the Board authorized the issuance of 125,000,000 shares of Common Stock to a related party on May 31, 2025, May 31, 2026, May 31, 2027, and May 31, 2028, in compensation for such services as an officer of the Company during the years then ended, if he is serving as treasurer on those dates.

On August 11, 2024, the Board authorized the issuance of 125,000,000 shares of Common Stock to a related party as compensation for his services as an officer of the Company for the year ended May 31, 2024, and the issuance of like amounts on May 31, 2025, May 31, 2026, and May 31, 2027, in compensation for such services during the years then ended, if he is serving as treasurer on those dates.

On August 12, 2024, the Company amended its amended and restated articles of incorporation to increase the number of shares designated Series A Preferred Stock from 1,000 to 2,000 and on August 11, 2024, the Board authorized the issuance of the 1,000 shares created by the amendment to a related party and the shares were issued by operation of law.

On September 3, 2024, one of the Company’s officers entered into a new lease for the apartment at 1625 Main St., Houston, Texas (see Note 10). The term of the lease begins on September 15, 2024, and ends on August 14, 2025. The officer intends to make a portion of these premises available to the Company for use as office space, for which the Company will pay him $2,817 per month.

Management has evaluated all other subsequent events when these consolidated financial statements were issued and has determined that none of them requires disclosure herein.

F-16

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosures.

None.

Item 9A.

Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Management, with the participation of the principal executive officer and principal accounting officer, has evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures, as this term is defined in Rule 13a-15(e) promulgated under the Exchange Act, as of May 31, ~~2024~~2025. Based on this evaluation, the principal executive officer and principal accounting officer concluded that these disclosure controls and procedures were not effective as of that date, at a reasonable level of assurance, in ensuring that the information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is (a) accumulated and communicated to the Company’s management, including its the principal executive officer and principal accounting officer, in a timely manner to allow timely decisions regarding required disclosure, and (b) recorded, processed, summarized and reported within the periods specified in the SEC’s rules and forms.

Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as this term is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that (a) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company; (b) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (c) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on its financial statements.

Under the supervision and with the participation of management, including the principal executive officer and principal accounting officer, the Company conducted an evaluation of the effectiveness of its internal control over financial reporting based on the criteria in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2017 framework) (“COSO”). Based on this evaluation, management concluded that internal control over financial reporting was not effective as of May 31, ~~2024~~2025. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. As defined in Rule 12b-2 promulgated under the Exchange Act, a material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement in the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. The Company’s evaluation of its internal control over financial reporting identified the following material weaknesses in internal control over financial reporting as of May 31, ~~2024~~2025:

	·	The Company has difficulty in accounting for complex transactions.

	·	Documented processes do not exist for several key processes.

	·	The Company lacks oversight by the Board because it has no directors who are independent of management and no audit committee.

Because of the material weaknesses noted above, the Company has concluded, based on COSO, that it did not maintain effective internal control over financial reporting as of May 31, ~~2024~~2025.

1922

Changes in Internal Control Over Financial Reporting

There were no changes in the Company’s internal control over financial reporting during the quarter ended May 31, 2024, that have materially affected, or are reasonably likely materially to affect, its internal control over financial reporting.

Attestation Report of the Independent Registered Public Accounting Firm

This report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting because it is not required for the Company pursuant to the rules of the SEC.

Item 9B.

Other Information.

Clawback Policy

On August 11, 2024, the Company adopted its clawback policy~~, which is attached as Exhibit 97 to this Report~~.

Insider Trading Policy

On August 11, 2024, the Company adopted its insider trading policy~~, which is attached as Exhibit 19 to this Report~~.

Insider Trading Arrangements and Related Disclosure

During ~~the~~ the three months ended May 31, ~~2024~~2025, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not applicable.

2023

PART III

Item 10.

Directors, Executive Officers and Corporate Governance.

The following table presents information with respect to our officers and directors:

Name	Age	Position
Dante Picazo	6869	Chief Executive Officer and Director
John Jones	5960	Treasurer and Director
Jose Torres Torres	64	Secretary and Director

Each of our directors serves until his death, resignation or removal or until his successor is elected and qualified. Each of our officers is elected by the Board for a term of one year and serves until his successor is duly elected and qualified or until he dies, resigns or is removed. Our directors receive no compensation for their services as such. Mr. Picazo receives no compensation for his services as an officer. Mr. Jones receives compensation for his services as treasurer pursuant to the Jones Agreement. See “Certain Relationships and Related Transactions, and Director Independence – Certain Relationships and Related Transactions – Jones Agreement.” Mr. Torres Torres will receive compensation for his services as treasurer. See “Certain Relationships and Related Transactions, and Director Independence – Certain Relationships and Related Transactions – Issuance of Shares to Officer.”

Biographical Information Regarding Officers and Directors

Dante Picazo

Mr. Picazo has been the chief executive officer and a director of the Company since the merger of PUI into the company on December 19, 2019, and was the co-founder of PUI, serving as one of its directors and as its chief executive officer and president from its incorporation in 2009 to that merger.

He has 45 years of experience in operating and growing from concept to profitability, originating marketing and branding efforts, leading to initial public offerings for three companies.

He graduated from Cornell University School of Hotel Administration, AMP in Ithaca, N.Y., and is fluent in three languages.

Mr. Picazo’s control of the Company through his ownership of its capital stock, together with his knowledge of the Pharmacology University Business and his extensive experience in international business and finance, led to the conclusion that he should serve as a member of the Board.

John Jones

On August 11, 2024, Mr. Jones was appointed by the Board to fill the vacancy in the Board created by the death of Henry Levinski on December 29, 2023, and as the Company’s treasurer.

He has 35 years of experience as a senior executive in the food services industry.

Mr. Jones is 59 years of age.

Mr. Jones’ ownership of a significant portion of the Company’s capital stock, together with his extensive experience in business, and his willingness to assist the Company in raising equity capital, led to the conclusion that he should serve as a member of the Board.

Jose Torres

Dr. Torres has served as a director and national medical director of the Company since the merger of PUI into the ~~company~~Company on December 19, 2019. He served in like positions with PUI until the merger. He is board-certified in General and internal medicine and is an Anti-aging medicine Specialist with 35 years of medical practice experience.

He received his medical degree from the Autonomous University of Guerrero in Chilpancingo, Guerrero, Mexico, and completed a residency in internal medicine residency at Caguas Regional Hospital in Puerto Rico. He is certified in urgent care and by World Link Medical. He is a Member of the American College of Physicians, the Puerto Rico College of Physicians and the American Academy of Cannabinoid Medicine. He is an expert in the medical uses of cannabis and is involved in research respecting its use in treating several medical conditions, including sleep disorders, pain management, treatment of nausea and vomiting associated with cancer and chemotherapy, asthma and other bronchial ailments, and decreased libido.

Mr. Torres’ experience with the medicinal use of cannabis and with sleep disorders led to the conclusion that he should serve as a member of the board.

Code of Conduct

The Board has adopted a Code of Conduct, which is applicable to all of the Company’s employees, officers (including its principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions), directors, agents and other parties acting on its behalf. A copy of this Code has been filed as an exhibit to this Report and is posted on the Company’s website at www.cbih.net. The Code may also be viewed by accessing the Company’s public filings at the SEC’s website at www.sec.gov. A copy of the Code will be provided without charge upon request by mail at the Company’s address shown on the cover page of this Report, to the attention of the chief executive officer.

The Company intends to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or a waiver from, a provision of its code of ethics that applies to the Company's principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions by posting such information on its website at www.cbih.net or by filing a Current Report on Form 8-K in relation to such amendment or waiver.

Clawback Policy

The Board has adopted a Clawback Policy that requires that, in the event of an Accounting Restatement, the Company will reasonably promptly recover Erroneously Awarded Compensation after an Accounting Restatement from executive officers. An “Accounting Restatement” is an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. “Erroneously Awarded Compensation” means the amount of incentive-based compensation received by him as an executive officer, that exceeds the amount of incentive-based compensation that he otherwise would have received had it been determined based on the restated amounts, computed without regard to any taxes paid. The Company has delivered no compensation that is subject to recovery under this policy.

Insider Trading Policy

The Board has adopted an Insider Trading Policy to promote compliance by officers, directors, employees and certain other persons who are aware of material nonpublic information about the Company with laws that prohibit them from trading in its securities or providing material nonpublic information to persons who may trade on the basis of that information. A copy of the Insider Trading Policy has been filed as an exhibit to this Report.

2225

Item 11.

Executive Compensation.

Compensation of Officers

The following table sets forth information concerning all compensation awarded to, earned by, or paid to our ~~principal~~ executive ~~officer,~~officers ~~who was our only executive officer serving on May 31, 2024,~~ for the fiscal years ended May 31, ~~2024~~2025, and May 31, ~~2023~~2024.

SUMMARY COMPENSATION TABLE

Name and principal position

Year

Salary ($)

Bonus ($)

Stock Awards ($)

Option Awards ($)

Non-equity incentive plan compensation ($)

Change in pension value and nonqualified deferred compensation earnings ($)

All Other Compensation ($)

Total ($)

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

Dante Picazo

~~2024~~2025

24,~~500~~000

–

24,~~500~~000

PEO and PFO

~~2022~~2024

24,500

–

2524,~~000~~500

John Jones

2025

75,000

–

75,000

Treasurer

2024

–

¹ Market value of 125,000,000 shares of Common Stock issued to Mr. Jones as compensation for his services.

Compensation Discussion and Analysis

The Company has determined the amount paid as salary to Mr. Picazo based solely on the Company’s ability to pay. The Company believes that his salary is substantially lower than he could earn in an equivalent position at another company and that he has elected to receive his salary and remain with the Company because of his equity position in the Company, his belief in the prospects of the Company and intangible reasons of ~~which~~ which the Company may not be aware. The Company believes that it needs to be able to provide competitive compensation to Mr. Picazo, as as well as to persons that it hires in the future, but will not be able to do so until it can generate materially increased revenue. Until then, the Company is subject to the risk that Mr. Picazo or persons that it may hire in the future will seek employment elsewhere. The Company has adopted its 2022 Equity Incentive Plan (see “Incentive Plan”) and may explore the adoption of plans that will enable it to reward and retain the loyalty of Mr. Picazo and other employees through awards of share-based compensation, such as stock options, restricted stock and restricted stock units.

Incentive Plan

General Information

On July 20, 2022, the Board adopted, and the shareholders approved, the 2022 Equity Incentive Plan (the “Incentive Plan”), which provides for the grant of stock options, stock appreciation rights, restricted stock, unrestricted stock, restricted stock units, and performance awards to directors, officers, employees and consultants (“Grantees”). The Incentive Plan is administered by the Board, which has the authority, among other things, to select eligible persons to receive awards and determine the terms of awards.

The Company will recognize as share-based compensation expense all share-based payments to Grantees over the requisite service period (generally the vesting period) in its consolidated statements of ~~income~~operations based on the fair values of the awards that are ultimately expected to vest. As a result, for most awards, recognized share-based compensation expense will be reduced for estimated forfeitures prior to vesting, primarily based initially on the judgment of management and thereafter, estimated forfeitures will be reassessed in subsequent periods based on facts and circumstances. As no awards were made under the Incentive Plan during the periods covered by the consolidated financial statements included in this Report, no expense for share-based compensation was recorded therein.

The Company adopted the Incentive Plan because it believes that long-term incentives for Grantees will be a significant factor in generating returns for its shareholders based upon the Incentive Plan’s ability to focus on long-term performance. By providing grantees with opportunities to acquire a meaningful equity stake in the Company, it can better align their interests with those of its shareholders and create value for them.

The Company expects to make periodic awards to its executive officers, employees and consultants, as well as awards in connection with promotions or new hires, the occurrence of significant events or to promote retention of employees.

Awards will generally be subject to time- or performance-based vesting over periods determined by the Board. Performance-based goals will be determined by the Board. We believe that performance-based awards will encourage Grantees to achieve key strategic objectives and maximize value creation for our shareholders.

No awards have been made as of the date of this Report.

Provisions of the Incentive Plan

The following is a description of the material terms of the Incentive Plan, which is not a complete description and is qualified in its entirety by reference to the Incentive Plan, which is filed as an exhibit to this Report.

Authorized shares. Subject to adjustment in certain events, the maximum number of shares of Common Stock that may be issued in satisfaction of awards is 600,000,000. As of the date of this Report, no awards had been granted.

Eligibility. The Board may select participants from among employees and directors of and consultants to the Company.

Types of awards; vesting. The Incentive Plan provides for various awards, including incentive stock options (“ISOs”), nonstatutory stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards and cash. The Board has the authority to determine the vesting schedule applicable to each award and to accelerate the vesting or exercisability of any award.

Termination of awards.

Unless otherwise provided in an award agreement, upon termination of employment or service, a participant’s options and SARS will terminate and the participant will have no further right, title or interest therein, the shares of Common Stock subject thereto or any consideration in respect thereof. If employment or service terminates otherwise than for cause, the Participant may exercise his Option or SAR to the extent vested, but only within the following period or, if applicable, such other period provided in the Award Agreement.

Except as otherwise provided in the Award Agreement or other written agreement, if a Participant’s continuous service terminates for any reason, (i) the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the participant under his restricted stock award that have not vested as of the date of such termination as set forth in such agreement and (ii) any portion of his RSU award that has not vested shall terminate upon such termination and he shall have no further right, title or interest in the RSU award, the shares of Common Stock issuable pursuant thereto the RSU Award or any consideration in respect thereof the RSU.

Except as provided in an award agreement, in the event of a dissolution or liquidation of the Company, outstanding awards (other than those consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company’s right of repurchase) shall terminate prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company’s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company, provided that the Board may cause some or all expired or terminated Awards to become fully vested, exercisable or no longer subject to repurchase or forfeiture before the dissolution or liquidation is completed but contingent on its completion.

Transferability.

Options and SARs may not be transferred to financial institutions for value and the Board may impose such additional limitations on the transferability of an option or SAR as it determines. In the absence of any such determination, the following restrictions shall apply (provided that, except as explicitly provided in the Incentive Plan, an option or a SAR may not be transferred for consideration and, if an option is an ISO, it may be deemed to be a nonstatutory stock option as a result of such transfer):

An option or SAR shall not be transferable, except by will or by the laws of descent and distribution, and shall be exercisable during the lifetime of a participant only by him (provided that, in certain cases, the Board may permit the transfer of an Option or SAR in a manner that is not prohibited by applicable tax and securities laws upon the Participant’s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section 671 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”), and applicable state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company.

Subject to the execution of transfer documentation in a format acceptable to the Company and subject to the approval of the Board or a duly authorized officer, an Option or SAR may be transferred pursuant to a domestic relations order.

Corporate transactions. In the event of certain corporate transactions (including merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure), the Board shall appropriately and proportionately adjust (a) the class or classes and the maximum number of shares of Common Stock subject to the Plan, (b) the class or classes and the maximum number of shares that may be issued pursuant to the exercise of ISOs and (c) the class or classes and the number of securities and exercise price, strike price or purchase price of Common Stock subject to outstanding Awards.

Acceleration. The Board may accelerate the time at which an award may first be exercised or the time during which an award or any part thereof will vest.

Change in control. In the event of a change in control of the Company (as defined in the Incentive Plan), the Board shall have discretion (i) settle awards for an amount of cash or securities equal to their value, where in the case of options and SARs, the value of such Awards, if any, shall be equal to their in-the-money spread value (if any), as determined in the sole discretion of the Board, (ii) arrange for the surviving corporation or acquiring corporation (or its parent company) to assume or continue the award or to substitute a substantially similar award, (iii) arrange for the assignment of any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to the award to the surviving corporation or acquiring corporation (or its parent company), (iv) modify the terms of awards to add events, conditions or circumstances (including termination of employment within any specified period after a change in control) upon which the vesting of such awards or lapse of restrictions thereon shall accelerate or deem any performance conditions satisfied at target, maximum or actual performance through closing or provide for the performance conditions to continue after closing, (v) arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to awards, (vi) cancel or arrange for the cancellation of awards, to the extent not vested or not exercised prior to the effective time of the change in control, in exchange for such cash consideration, if any, as the Board may consider appropriate, or(vii) provide that, for at least 20 days prior to the change in control, any Options or SARs that would not otherwise become exercisable prior thereto shall be exercisable as to all shares of Common Stock subject thereto, contingent upon and subject to the occurrence of the change in control, and that any options or SARs not exercised prior to the consummation of the change in control shall terminate and be of no further force and effect as of the consummation thereof.

Amendment and termination. The Board may amend the Incentive Plan or outstanding awards, except that it may not materially impair the rights and obligations under any award except with the written consent of the affected participant.

Retirement, Resignation or Termination Plans

We have or sponsor no plan, whether written or verbal, that would provide compensation or benefits of any type to an executive upon retirement or any plan that would provide payment for retirement, resignation, or termination as a result of a change in control of our company or as a result of a change in the responsibilities of an executive following a change in control of our company.

Pension Benefits

The Company has no plan under which retirement payments and benefits, or payments and benefits that will be provided primarily following retirement may be or have been or may be paid.

Nonqualified Defined Contribution and Other Nonqualified Deferred Compensation Plans

The Company has no defined contribution or other plan that provides for the deferral of compensation.

Potential Payments upon Termination or Change-in-Control

The Company is not a party to any contract, agreement, plan or arrangement, whether written or unwritten, that provides for payment to any of its executive officers at, following or in connection with any termination, including without limitation resignation, severance, retirement or constructive termination, or a change in control of the Company or a change in any of their responsibilities.

Compensation of Directors

Pursuant to the provisions of the Jones Agreement (see Item 13 – Certain Relationships and Related Transactions, and Director Independence – The ~~directors~~Jones ~~receive~~Agreement), noJohn ~~compensation~~Jones ~~for~~was ~~their~~issued 100,000,000 shares of Common Stock in consideration of his services as ~~such.~~a director during the year ended May 31, 2025, and is entitled to receive like numbers of shares on May 31, 2026, May 31, 2027, and May 31, 2028, provided that he is serving as a director on those dates,

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The following table provides information with respect to the beneficial ownership of Common Stock by the following (i) each of our named executive officers, (ii) each of our directors, (ii) all directors and executive officers as a group, (iii) each person known to the Company to beneficially own more than 5% of Common Stock (excluding the Selling Stockholders) and (iv) the Selling Stockholders. The amounts and percentages of shares of Common Stock beneficially ~~owned~~ owned are reported as required by the SEC’s rules respecting the determination of beneficial ownership of securities. Under these rules, a person is deemed to be a “beneficial owner” of a security if he has or shares voting power or investment power, which ~~includes~~ includes the power to dispose of or to direct the disposition of such security and is also deemed to be a beneficial owner of any securities of of which he has a right to acquire beneficial ownership within 60 days after the determination date. Securities that can be so acquired ~~are~~ are deemed to be outstanding for purposes of determining such person’s ownership percentage, but not for purposes of determining ~~any~~ any other person’s ownership percentage. Under these rules, more than one person may be deemed to be a beneficial owner of the same securities and a person may be deemed to be a beneficial owner of securities in which he has no economic interest.

Name and Address of Beneficial Owner1	Title of Class or Series	Number of Shares Beneficially Owned		Percent of Outstanding ~~Shares~~Shares2
Dante Picazo	Common Stock	4,002,611,700	2	34.1	~~38.7~~	3
	Series A Preferred	2,000,000		80.0	~~80.0~~
	Series B Preferred	1,000		50.0	~~50.0~~
John Jones	Common Stock	12,~~103~~123,888,888		18.1		3
	Series B Preferred	1,000		50.0	~~50.0~~
Jose A. Torres Torres	Common Stock	40,000,000		–	~~10.6~~	3
All directors and executive officers as a group (3 persons):	Common Stock	5,146,500,888		49.3	~~49.3~~	3
	Series A Preferred	2,000,000		80.0	~~80.0~~
	Series B Preferred	2,000		100.0	~~100.0~~
Ibeth Coralles	Common Stock	625,000,000		5.3	~~5.9~~	3

(1) The address for each person is c/o ~~Cannabis~~ Cannabis Bioscience International Holdings, Inc., 6201 Bonhomme Road, Suite 435N, Houston, TX 91789.

(2) Based on 1011,~~431~~476,749,347 shares of Common Stock outstanding on the date of this Report, plus the 2,500,000 shares of Common Stock into which the outstanding shares of Series A Preferred Stock are convertible, totaling 1011,~~434~~749,249,347 shares of Stock. Mr. Picazo has the right to acquire 2,000,000 shares of the ~~shares of~~ Common Stock into which the outstanding shares of Series A Preferred Stock are convertible.

~~(3) Includes 117,000 shares of Common Stock beneficially owned together with another person.~~29

Item 13.

Certain Relationships and Related Transactions, and Director Independence.

Affiliate Loan.

~~The~~On May 1, 2025, the Company made a promissory note in the principal amount of $~~291~~340,~~451~~855 in favor of John Jones and Barbara Kamienski (the “Jones Note”). The Jones Note ~~matures on April 25, 2025,~~ bears interest at the rate of 102.5% per annum and is repayable in 10 monthly installments of $298,~~145.~~521, beginning on May 31, 2025, until paid in full. Events of default include failure to pay principal or interest when due, breach of covenant, breach of representation and warranty, assignment for the benefit of creditors or appointment of a receiver, bankruptcy and cessation of operations. The Jones Note replaces ~~promissory~~several promissory notes previously made by the Company in favor of Mr. Jones and Ms. Kamienski. ~~Certain provisions of the Jones Note have been modified. See “The Jones Agreement,” immediately below.~~ A copy of the Jones Note is annexed to this Report as Exhibit 10.17 and the description of its provisions is qualified in its entirety by reference thereto.

The Jones Agreement.

Pursuant to the Jones Agreement, (i) Mr. Jones ~~agreed~~made ~~make~~ a payment of $37,500, due on September 15, 2024, under a Securities Purchase Agreement, dated as of March 14, 2024, by and ~~between~~ between the Company and 1800 Diagonal Lending LLC, a Virginia limited liability company (the “Diagonal SPA”), (ii) Jones and ~~Kamienski~~ Kamienski agreed to reduce (A) the rate of interest on the Jones Note to 2.5% monthly, effective as of the date of its making, and (B) ~~establish~~ establish a monthly payment of $5,000 until the Jones Note is paid in full, (iii) the Company, agreed to appoint Jones as a and treasurer of the Company, (iv) in consideration of Jones’ services as treasurer, the Company agreed to issue to Jones 125,000,000 shares of its Common Stock on each of May 31, 2025, May 31, 2026, May 31, 2027, and May 31, 2028, provided that he is serving as treasurer on those dates, (v) in consideration of Jones’ services as a director, the Company agreed to issue to Jones 100,000,000 shares of its Common Stock on each of May 31, 2025, May 31, 2026, May 31, 2027, and May 31, 2028, provided that he is serving as a director on those dates, and (v) Jones agreed that, in consideration of 1,000 shares of Series B Preferred Stock, during a period ending on the first anniversary of the Jones Agreement, he will make efforts to raise $250,000 in equity for the Company on terms satisfactory to it.

A copy of the Jones Agreement is annexed to this Report as Exhibit 10.13 and the description of its provisions is qualified in its entirety by reference thereto.

The Vita Agreement.

On May 1, 2024, Vita Biotech Research LLC (“Vita”) and Alpha Research Institute LLC (“Alpha”), the Company’s wholly owned subsidiary, entered into a Master Research Agreement (the “Vita Agreement”), under which Vita engaged Alpha to conduct several clinical trials for the Vita for the purpose of collecting and providing medical data to be used in the creation of vitamins, nutraceuticals and all other general medicinal development, as long as doing so is within the legal parameters permitted in Texas and Colombia and other countries, determined by one or both of the parties.

Under this agreement, Alpha is required to have at least one of its physicians serve as the principal investigator for each collection initiative, with one or more subinvestigators assigned thereto. No physician shall serve as principal investigator or subinvestigator without Alpha’s consent. The Institution shall cause each principal investigator and each subinvestigator to conduct the collection Initiatives in strict adherence to the relevant protocol. Alpha will establish the terms under which confidential information will be shared and protected. Alpha will make the principal investigator and all subinvestigators, employees, contractors, and agents of Alpha who are to perform any work in connection with a collection initiative aware of the obligations contained in the Vita Agreement and the applicable work orders and will bind them thereto. Vita is solely responsible for developing protocols.

Because the data recollected from biospecimens is experimental and may have unknown characteristics, Alpha is obligated to use prudence and reasonable care in their use, handling, storage, transportation, disposition, and containment and has agreed that it will be legally responsible for the data collected from biospecimens until the Vita or a downstream researcher takes custody of them, in accordance with a work order. Because the collection and transfer of biospecimens and associated data is highly sensitive, Alpha has warranted that biospecimens have been or will be collected, processed, tracked, stored, de-identified and transported in a manner appropriate to ensure compliance with the ethical regulations and guidelines established by the Declaration of Helsinki (2013), the recommendations of the International Society for Biological and Environmental Repositories, all requirements of an IRB, all applicable international and national (including state and local) laws, rules, regulations, ethical standards, including applicable privacy and patient confidentiality laws that exist where Alpha operates. Alpha will require the Principal Investigator or applicable Subinvestigators to report any adverse events experienced by a subject as a result of his participating in a collection initiative to both parties within forty-eight (48) hours of learning of such event and to be recorded.

Vita will pay Alpha $50,000 monthly, payment to be made within 30 days of receipt of the invoice (issued after all patients have been collected). All payments are contingent upon acceptance of the biospecimens and associated data. Termination

The Vita Agreement commenced on May 1, 2024, and has a term of 4 months. It will automatically renew for additional 4-month terms unless either party gives notice of termination at least 30 days before the end of the then current term.

A copy of the Vita Agreement is annexed to this Report as Exhibit 10.15 and the description of its provisions is qualified in its entirety by reference thereto.

Issuance of Shares to Officer.

On August 11, 2024, the Board adopted resolutions authorizing the issuance of 125,000,000 shares of Common Stock to Jose Torres Torres in compensation for his services as secretary of the Company for the year ended May 31, 2024, and like amounts on May 31, 2025, May 31, 2026, and May 31, 2027, in compensation for such services during the years then ended, if he is serving as secretary on those dates.

Advances

The Company has, from time to time., received advances from Dante Picazo, its chief executive officer, and Henry Levinski, its former vice president. All of these advances are non-interest-bearing and have no set maturity date. The Company expects to repay these advances when funds become available. During the years ended May 31, ~~2024~~2025, and May 31, ~~2023~~2024, the Company received and repaid advances as follows:

	Dante Picazo			Henry Levinski
Balance at May 31, 2023	$	~~(45~~12,485	)		1592,~~883~~643
Year ended May 31, 2023:
Year ended May 31, 2024:
Amounts advanced		121,~~530~~184			864,~~440~~420
Amounts repaid		–			(9,860	)
Balance at May 31, 2023	$	12,485		$	92,643
Year ended May 31, 2024
Amounts advanced		100			4,420
Amounts repaid		–			–
Balance at May 31, 2024	$	1213,~~585~~559		$	9792,~~063~~643
Year ended May 31, 2025
Amounts advanced		33,518			4,420
Amounts repaid		–			–
Balance at May 31, 2025	$	47,188		$	101,483

~~Since~~In the years ended May 31, ~~2024~~2025, and May 31, 2024, Mr. Picazo ~~has~~ advanced $0 33,518 and $1,184 to the Company and has been repaid $0;. Mr. Levinski’s estate has been repaid $0. At September 10, ~~2024~~2025, the balances that the Company owed to Mr. Picazo and Mr. Levinski’s estate were $1243,~~585~~114 and $97101,~~063~~483, respectively.

Apartment Lease

On September 3, 2023, Messrs. Picazo Levinski entered into a lease for 1,400 square feet in Houston, Texas, at 1625 Main St, Houston, Texas, the term of which commenced on September 15, 2023, and expired on September 14, 2024, at a rent of $3,164 per month and made a portion of these premises available to the Company for use as office space, for which the Company paid them $2,817 per month. These officers entered into a new lease for these premises, which commenced on September 15, 2023, and expired on September 14, 2024, at a rent of $3,164 per month and they made a portion of these premises available to the Company for use as office space, for which the Company paid them $2,817 per month. On September 3, 2024, Mr. Picazo entered into a new lease for these premises. The term of the lease began on September 15, 2024, and expired on August 14, 2025. The lease has not been renewed and under its terms, it has been renewed on a month-to-month basis. Messrs. Picazo and Levinski made a portion of these premises available to the Company ~~believes~~for ~~that~~use as office space under the ~~rental~~earlier ~~represents~~lease, and Mr. Picazo has continued to do so under the later lease, for which the Company has paid them and him $2,817 per month. The Company believes that these rentals represent the fair market value of the space rented and that the amount that Messrs. Picazo and Levinski ishave ~~charging~~charged the Company for its use of a portion of the area occupied by them is proportional to the total area rented by them.

Director Independence

OTC Markets Group Inc. defines “independent director” as a person other than an executive officer or employee of a company or any other person having a relationship which, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out their responsibilities as a director. The persons who are not considered independent for purposes of this definition are (i) a director who is, or at any time during the past three years was, employed by the company; (ii) a director who accepted or has a family member who accepted any compensation from the company in excess of $120,000 during any fiscal year within the three years preceding the determination of independence, other than compensation for board or board committee service; compensation paid to a family member who is an employee (other than an executive officer) of the company or benefits under a tax-qualified retirement plan, or non-discretionary compensation or (iii) a director who is the family member of a person who is, or at any time during the past three years was, employed by the Company as an executive officer.

Inasmuch as all of the directors of the Company are employed by the Company as its officers, none of them is an independent director.

A director is not considered independent if he is also an executive officer or employee of the corporation.

Compensation Committee

The Company does not have a standing compensation committee or a committee performing similar functions because the Board believes that, in light of the Company’s early stage of development and the fact that its compensation structure is not complex, such a committee is not presently warranted. Accordingly, the whole Board participates in considering executive compensation and will do so if, in the future, directors are compensated for their services as such.

Item 14.

Principal Accountant Fees and Services.

Audit Fees

The Company was billed $1725,~~500~~000 and $2517,~~000~~500 by Victor Mokuolu, CPA PLLC (“VMCPA”), the Company’s independent registered public accounting firm and its principal accountant, for the years ended May 31, ~~2024~~2025, and May 31, ~~2023~~2024, respectively, for its professional services rendered for the audit of the Company’s annual financial statements, the review of the financial statements included in its quarterly reports on Form 10-Q or and other services normally provided in connection with its statutory and regulatory filings or engagements for those years.

Audit-Related Fees

The Company was billed $1512,000 and $2015,000 by VMCPA for audit-related fees for the years ended May 31, ~~2024~~2025, and May 31, ~~2023~~2024, respectively. Audit-related fees include fees for assurance and related services rendered by the principal accountant and which were reasonably related to the performance of the audit or review of the Company’s financial statements.

Tax Fees

The Company was billed $0 for fees by VMCPA for professional services for tax compliance, tax advice and tax planning for the years ended May 31, ~~2024~~2025, and May 31, ~~2023~~2024.

Other Fees

There were no fees for professional services rendered by VMCPA during the last two fiscal years that were not included in the above paragraphs.

Preapproval Policy

None of the above services was approved by an audit committee because the Board has no such committee. The Board has pre-approved all audit and permissible non-audit services provided by its principal accountant.

2932

PART IV

Item 15.

Exhibits, Financial Statement Schedules.

Financial Statements and Schedules. The following financial statements and schedules for the Company as of May 31, 2024, are filed as part of this report.

(a)

Consolidated Financial Statements of the Company.

See Item 8, Financial Statements and Supplementary Data – Index to Consolidated Financial Statements.

Financial statement schedules have been omitted because they are not applicable or because the required information is shown in the financial statements or the notes thereto.

(b)

Exhibits.

Exhibit Number	Description
3.1	Amended and Restated Articles of Organization, filed with the Secretary of State of the State of Colorado on July 20, 2022.**
3.2	Amendment to the Articles of Incorporation, filed with the Secretary of State of the State of Colorado on December 6, 2022.**
3.3	Amendment to the Articles of Incorporation, filed with the Secretary of State of the State of Colorado on August 12, 2024.**
3.4	By-Laws. **
10.1	2022 Incentive Award Plan.+**
10.2	Lease, dated April 16, 2024, by and between 6201 Bonhomme, L.P. as landlord and the Registrant, as tenant (the Bonhomme Lease”).**
10.3	Apartment Lease, dated September 6, 2023, by and between SPUSG HSTN North Tower, as Lessor, and Dante Picazo and Henry Levinski, as tenants.**
10.4	U.S. Small Business Note, dated April 16, 2021, made by Elizabeth Hernandez and assumed by the Registrant.**
10.5	Forward Purchase Agreement (Fixed ACH Delivery), dated May 13, 2022, by and between Kapitos LLC and the Registrant.**
10.6	First Electronic Bank Revolving Credit Agreement, dated December 10, 2020, by and between Registrant and First Electronic Bank.**
10.7	Business Line of Credit Agreement, dated October 8, 2019, by and between Headway Capital, LLC and Pharmacology University, Inc.**
10.8	Future Receivables Sale and Purchase Agreement, dated as of August 8, 2022, by and between Park Avenue Funding and the Registrant.**
10.9	Clinical Trial Agreement, dated as of August 19, 2022, by and between Alpha Research Institute, LLC and Pharmaceutical Research Associates, Inc.**
10.10	Master Research Services Agreement, dated as of June 9, 2021, by and between the Registrant and SeraTrials, LLC and amendments thereto.**
10.11	Future Receipts Sale and Purchase Agreement, dated April 20, 2023, by and between Cloudfund LLC and the Registrant.**
10.12	Future Receivables Sale and Purchase Agreement, dated March 30, 2023, by and between Amerifund Group LLC and the Registrant.**
10.13	Agreement, dated July 26, 2024, by and among the Registrant, John Jones, Barbara Kamienski and Dante Picazo.+
10.14	Master Research Agreement, dated May 1, 2024, by and between Vita Biotech Research LLC and Alpha Research Institute LLC.**
10.15	Securities Purchase Agreement, dated March 14, 2024, by and between the Registrant and 1800 Diagonal Lending LLC.**
10.16	Promissory Note, dated March 14, 2024, made by the Registrant in favor of 1800 Diagonal Lending LLC.**
10.17	Promissory Note, dated ~~April~~May 301, ~~2024~~2025, made by the Registrant in favor of John Jones and Barbara Kamienski.*
10.18	Apartment Lease, dated September 3, 2024, by and between SPUSG HSTN North Tower, as Lessor, and Dante Picazo as tenant.**
10.19	Amendment of Bonhomme Lease (Exhibit 10.2)*
14	Code of Conduct.**
19	Insider Trading Policy.**
21	Subsidiaries of the Registrant.**
31	Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer and Principal Financial Officer.*
32	Section 1350 Certification of Principal Executive Officer and Principal Financial Officer.*
97	Clawback Policy.**
101.INS	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SC H	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

101.INS	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SC H	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

________________

	*	Filed herewith
	**	Filed previously
	+	Management contract or compensatory plan.

(b)

Financial Statement Schedules.

All schedules are omitted because the required information is either not present, not present in material amounts or is presented within the consolidated financial statements included in this Report.

Item 16.

Form 10-K Summary.

None

3134

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

September 1322, ~~2024~~2025

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.

/s/ Dante Picazo
Dante Picazo Chief Executive Officer

POWER OF ATTORNEY

Signature	Title	Date

/s/ Dante Picazo	Director, Chief Executive Officer,	September 22, 2025
Dante Picazo	Principal Executive Officer and
	Principal Financial Officer


/s/ John Jones	Director	September 22, 2025
John Jones


/s/ Jose A. Torres Torres	Director	September 22, 2025
Jose A. Torres Torres

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dante Picazo as his attorney-in-fact, each with the full power of substitution, for such person, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might do or could do in person hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or his substitute, may do or cause to be done by virtue hereof.35

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Dante Picazo	Director, Chief Executive Officer,	September 13, 2024
Dante Picazo	Principal Executive Officer and
	Principal Financial Officer
/s/ John Jones	Director	September 13, 2024
John Jones
/s/ Jose A. Torres Torres	Director	September 13, 2024
Jose A. Torres Torres

Filing Compare · Cannabis Bioscience International Holdings, Inc.